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Tiivistelmä: 
Apteekkilainsäädäntö on osa terveysoikeutta. Valtion intressinä on säädellä 
apteekkialaa lääketurvallisuuden, lääkkeiden kohtuullisten hintojen ja kansalaisten 
yhdenvertaisten apteekkipalvelujen takaamiseksi. Tämä tutkmus vertailee Suomen ja 
Norjan apteekkijärjestelmiä, niiden kehitystä ja kummankin maan apteekkijärjestelmän 
taustalla vaikuttavia keskeisiä tavoitteita ja oikeusperiaatteita. Tutkimuksen vertailu on 
luonteeltaan funktionaalista ja se keskittyy oikeusjärjestelmien mikrotasoon. 
Maiden järjestelmät ja lainsäätäjän tavoitteet ja niiden kehitys ovat samanlaiset. 
Kummassakin maassa apteekkitoiminta on luvanvaraista, lääkekuluja korvataan 
sosiaalivakuutuksella ja niissä on käytössä hintasääntely, geneerinen substituutio sekä 
viitehintajärjestelmä. Pääasialliset erot liittyvät apteekkien omistamiseen, 
apteekkimaksuun ja käsikauppatuotteiden myyntiin apteekkien ulkopuolella.  
Oikeusperiaatteita kuten ihmisarvon loukkaamattomuutta, oikeutta terveyteen, 
potilaan itsemääräämisoikeutta ja yhdenvertaisuutta sovelletaan myös lääkehuollon 
puitteissa. Nämä periaatteet näkyvät myös perusteluissa, jotka lainsäätäjä on esittänyt 
alaa koskevien säädösten valmistelumateriaaleissa. Resurssien niukkuuden takia 
hyvinvointivaltion lainsäätäjän on vähennettävä kuluja. Oikeusjärjestelmän syvemmillä 
kerroksilla toimivat terveysoikeuden periaatteet sekä perusoikeudet vaikuttavat 
lainsäätäjän terveydenhuollon säästätoimenpiteitä koskevien arvostelmien sisältöön. 
Julkinen keskustelu terveydenhuollon ammattilaisten, lakimieskunnan ja etujärjestöjen 
välilä on välttämätöntä näiden arvostelmien oikeudenmukaisuuden varmistamiseksi.  
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Abstract: 
Pharmacy law is part of health law. The state has an interest in regulating the sector in 
order to ensure drug safety, equal access to pharmaceutical care and affordable drugs. 
This research compares the pharmacy systems in Finland and Norway, their 
development, and the central aims and legal principles behind the choice of pharmacy 
system in each country. Comparison under this research is functionalist in nature and 
focuses on the micro-level of the two legal systems. 
The Finnish and Norwegian systems and the aims of the legislator have developed in a 
similar manner. In both countries pharmacy business is subject to license, 
pharmaceutical prices are controlled, drug costs are covered by a social insurance 
scheme and generic substitution and reference pricing are applied. The main 
differences relate to pharmacy ownership, the pharmacy fee and sale of overt-the-
counter drugs outside of pharmacies. 
Principles such as human dignity, right to health, the patient’s right to self-
determination and equal treatment apply in pharmaceutical care. Legal principles are 
evident in the legislator’s reasoning in preparatory materials for pharmacy law. Due to 
scarce resources the welfare state’s legislator needs to reduce costs. The requirements 
of fundamental rights and principles of health law, working on a deeper level of the 
legal system, impact the substance of the legislator’s valuations regarding savings in 
the healthcare sector. Public discourse between healthcare professionals, the legal 
profession and interest groups is necessary for ensuring justice in these valuations.  
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1. Introduction 
One of the central challenges of any state is to provide accessible healthcare services 
of adequate quality to all citizens. The Nordics have become an example of a welfare 
state model in which healthcare costs are covered by the public sector with funds 
collected from employers and tax payers, and in which the cost of healthcare for 
individual citizens is relatively low. However, due to the recession in 2009, several 
years of poor economic growth, and an ageing population, healthcare costs are 
growing in the Nordics and the pressure to contain them is rising. 
The means by which the legislator can impact healthcare costs are limited. The needs 
of individual patients cannot be regulated, only the manner in which to organize and 
allocate funds for servicing those needs. One characteristic feature of health law is that 
the decisions which most directly impact individual patients are made by doctors on a 
case by case basis and in accordance with professional standards. This very personal 
process cannot be easily interjected by the legislator with regulation on which choices 
should be made in the doctor-patient relationship. Thus, regulation concerning 
healthcare is focused on structures and administration, professional standards, 
measures to protect patients’ rights and legal remedies for malpractice. 
One field of healthcare, however, is different in nature and has developed into a 
private business in most countries. The distribution of medicinal products in 
pharmacies works like an outsourced branch of public healthcare. Pharmacy as a field 
of healthcare is different from medical care in one central aspect: in addition to 
pharmaceutical service, distribution of medicinal products to a patient constitutes a 
transaction. In providing a physical product, as opposed to a service such as a medical 
procedure, the activity becomes concrete and its regulation can be approached in a 
more conventional and instrumental manner than the rest of healthcare. 
There are various interests which need to be consolidated when drafting legislation 
relating to pharmaceutical distribution. The market for medicinal products in Norway 
was NOK 21.4 billion (EUR 2.6 billion)1 in total turnover in 2014. In Finland, the total 
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sale of medicinal products was EUR 2.8 billion2 in 2013. Actors in the pharmaceutical 
industry, including manufacturers, importers and wholesale companies, aim at 
securing profit for shareholders as well as capital for research and development. 
Pharmacy owners view themselves both as entrepreneurs as well as healthcare 
professionals and aim at ensuring the best service for customers while maintaining a 
profitable business. From the perspective of the state, pharmaceutical distribution 
needs to be organised in a just but cost-efficient manner. Customers and patients have 
an interest to ensure autonomy in regard to their treatment, the lowest possible 
medical expenses and easy access to pharmacy services. 
Within the pharmacy sector, everyday business activities are regulated in detail. 
Simultaneously, pharmacists work in close cooperation with the public healthcare 
system and adhere to the same ethical standards as other healthcare professionals. 
This work aims at providing an overview of the factors which have led to such detailed 
regulation of pharmaceutical distribution in Finland and in Norway. Furthermore, I will 
use a comparative approach in order to analyse these factors and to systemise the 
legal principles which bind the legislator when enacting new norms in the field.  
Healthcare is a central question within the welfare state and consequently the 
relatively new field of health law has been brought up to contribute to the discussion. 
However, in public discussion, the framework for providing healthcare is primarily 
referred to as a political question. In an environment of challenging state economy, 
discussion regarding healthcare is focused on resource allocation and cost-efficiency. 
Under such circumstances the legislator faces numerous choices between policy 
options which are based on political factors as well as on law. There is a distinct need 
for distinguishing the legal principles and the minimum legal requirements regarding 
human dignity and fundamental human rights from the political questions regarding 
healthcare when making legislative reforms as well as policy decisions in the field. 
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2. Research Objective and Paradigm 
I have started this research with the knowledge that until 2000 the pharmacy systems 
in Finland and Norway were very similar to each other. In 2001 the Norwegian system 
underwent a significant reform, while Finland has kept the main features of its 
pharmacy system unaltered. The central questions which this research aims to answer 
are as follows: 
How do the pharmacy systems in Finland and Norway differ from each other today? 
Why are the systems different or similar? What are the central aims and legal 
principles behind the choice of pharmacy system in each country? 
The work aims at identifying which legal principles and other considerations the 
legislator in Finland and Norway has taken into consideration in legislation regulating 
the pharmacy sector and medicinal products. Legal principles have been distinguished 
from political aims and policies. The research examines the demands of human rights 
and legal principles on the legal framework for distribution of pharmaceuticals. 
Within this work I have aimed at a high level of transparency in regard to the utilized 
research methods and source materials as well as the social context in which I have 
carried out this research. The paradigm of this research is that there are certain 
fundamental human and social rights regarding health which bind the legislator. 
The principal aim of this work is to provide an overview of the legal framework of 
principles and individual rights regarding pharmaceutical distribution which are 
common for Nordic welfare states. This aim is best served by conducting comparative 
research as described in more detail in section 3.4. This research objective is closely 
linked to the paradigm of this research. I have attempted to approach the research 
objective with recognisable methods of legal research which provide an accurate 
formulation of the topic. However, it is evident in the paradigm of the research that as 
a researcher I have not fully eliminated my subjective perception of the matter or the 
social context in which I am conducting my research, nor have I attempted to do so. 
The systemisation and the results of the legal comparison reached on the basis of the 
research paradigm highlight the role of fundamental human and social rights within 
the pharmacy sector and healthcare. 
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3. Research Methods 
3.1. Formulating a Method 
In order to conduct research in a productive manner which serves the knowledge 
interest outlined for the research, the researcher needs to formulate a method. This 
work is a comparative study of the pharmacy system of two countries and thus it falls 
within the scope of comparative law. Comparative law does not have a singular 
prescribed method which all researchers are required to strive for. On the contrary, 
comparative law research can employ and combine different methodological 
approaches and theories for its use. The combination of approaches should be chosen 
in the manner that best serves the knowledge interest of the research. 
The following chapters outline the methodology used for this research within the 
larger context of legal science and legal research, the different methods of legal 
research employed to support law comparison, and the methodological choices made 
in the comparative research. 
3.2.  Fields and Methods of Legal Research 
Legal science, as understood in a wide sense of the term, includes the following fields 
of legal research: doctrinal study of law, historical study, sociology of law, law and 
economics and comparative study of law.3 In this work I will practise comparative 
study (Rechtsvergleichung) as well as doctrinal study of law (Rechtsdogmatik). 
Research can have different aims, which all warrant different methods. Aarnio uses the 
distinction between explanatory or non-explanatory research when describing the 
research method of legal science. This distinction clarifies whether or not the research 
is used to explain the causal relationship for example between two phenomena. 
Explanatory research aims at explaining the background of norms or court decisions by 
relying either on causal or finalistic explanation. Non-explanatory research does not 
attempt to explain why a certain phenomenon has come to existence or why it has 
developed in a certain manner. Instead, non-explanatory research describes and 
defines the phenomenon or the stages of its development as such. Aarnio makes a 
distinction also regarding the content of research. Legal research can be normative or 
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non-normative. The nature of normative research is to present norms, that is, 
prescriptive utterances while the results of non-normative research are in the form of 
descriptive statements. Thus, the distinction clarifies whether the research aims at 
describing how something should be or if the goal is to describe how something is. 
According to Aarnio, the traditional research objective of the doctrinal study of law is 
non-explanatory and normative. The aim of such research could for example be to 
describe how the legal system treats pharmaceutical patents and how difficult cases 
should be treated in court when the written acts of law are open to interpretation. 
This kind of research systemizes and restates norms, for example in order to present 
them in a more understandable or useful manner for the purposes of the research. 
Legal science also includes research which is non-explanatory and non-normative, for 
example in the form of presenting legal statutes or precedents without systemisation 
or restatement of norms. However, legal science cannot be explanatory and 
normative, because explanation as understood here cannot present norms as its 
result.4 
The last combination of these two distinctions is explanatory and non-normative 
research. Aarnio finds the attempt to provide a comprehensive description of legal 
science by defining it as explanatory and non-normative to be problematic. In natural 
sciences, where the research target is external and objective in relation to the 
researcher, research is conducted through logical deduction and induction and it is by 
nature explanatory and non-normative.5 However, in legal science the researcher is 
part of the social reality examined in the research. Thus, in practice deduction and 
induction are not used for legal interpretation. This research does not attempt to 
derive legal principles from individual norms through induction. Aarnio has however 
discussed the possibility of explanatory, non-normative research in the form of 
finalistic explanation of the origins of legislative acts.6 
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 See Aarnio, Aulis, Laki, teko ja tavoite p. 222–247 for an overview of attempts by legal theorists to 
support the use of deduction and induction in legal science. 
6
 Aarnio, Aulis, Laki, teko ja tavoite p. 219–220. 
6 
 
Aarnio distinguishes three different phases in scientific research: description, 
explanation and prediction.7 This research has been conducted mostly at the level of 
description. In conducting comparative research, I describe and restate norms 
concerning medicinal products and the relevant pharmacy systems. In this sense my 
research makes use of the method of doctrinal study of law. I also make some 
attempts at explanation as described below. This research does not include any 
prediction of court decisions or of the behaviour of public authorities and officials and 
thus prediction as a level of research is not discussed further. 
This work includes doctrinal study of law (non-explanatory and normative) to the 
measure that it aims at describing and systemising norms which apply to pharmacies 
and medicinal products. Identifying and restating the EU legislation and other 
international measures which are binding in Finland and Norway are also exercises in 
the doctrinal study of law. I will approach the task of systemisation with the research 
paradigm in mind. Systemisation begins with defining the relevant legislative acts and 
other legal sources which provide the basis for formulating and reformulating the 
system.8 
During the comparative stage of research, I will examine preparatory works and policy 
memoranda in order to explain the legislator’s choices. This kind of research, when it 
aims at explaining why the relevant norms were enacted, can be described as finalistic 
explanation. According to Aarnio, this method is explanatory and non-normative. Any 
explanatory features in my research method are in nature finalistic explanation and I 
make no claims of verifying my statements regarding the legislator’s intent by 
induction. Instead, the reasoning involved in this work is more accurately described as 
practical inference.  
Finalistic explanation focuses on examining the behaviour of the legislator or the public 
officials, such as courts, responsible for applying the law. This approach treats their 
behaviour as acts which have been carried out in order to achieve a particular goal. 
Finalistic explanation is in practice often used by legal practitioners and legal scientists 
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as the initial stage of legal interpretation. For example, the purpose which the 
legislator has intended for a legislative act may influence the interpretation of the text 
of the act. However, the purpose may not be evident in the text of the act itself. In this 
case the goal for using finalistic explanation is to discover the ratio and voluntas of law. 
However, finalistic explanation can also be conducted independently and its findings 
can be valuable as such.9 
According to Tuori, there is an underlying tension between the concepts of ratio and 
voluntas within the legal system. The voluntas of law refers to the will of the legislator 
and to the political aims which the legislator wanted to advance with a particular act of 
law. The ratio of law on the other hand refers to the principles and reasoning found in 
the deeper, underlying layers of legal culture. The power of ratio is in its “logical 
persuasiveness, normative consistency or rational coherence”10. Thus, ratio promotes 
consistency and predictability in legal decision-making and it is evident in tradition and 
the coherence of the existing system. Under modern law, voluntas has however gained 
prominence. New legislation is increasingly interventionist, that is, legislation is used 
for correcting anomalies or adverse effects of policies instead of creating a stable 
framework for a larger domain in society. This increasingly instrumental role of justice 
and law in society has made the legislator’s aims and policies, and thus voluntas, more 
prominent. Such a shift towards highlighting voluntas however calls for a 
corresponding promotion of ratio. On the other hand, Ratio can no longer be seen only 
as traditional reason. Instead, arguments of coherence, fundamental principles of 
modern law, morality and ethics should all be employed in the exercise of discovering 
the ratio of law. Tuori describes legal culture as a result of sedimentation to which the 
above arguments as well as different legal and judicial practices have all contributed.11  
Legislation regarding medicinal products and the pharmacy sector is by nature very 
instrumental. Therefore, considerations regarding ratio and voluntas are central for 
understanding the reasons why the pharmacy systems in Finland and Norway have 
developed in the way they have. Ratio is a central question for understanding the legal 
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principles which apply in the pharmacy sector. Voluntas can be discovered by 
examining the legislator’s aims and choices. Aarnio distinguishes the following 
problems in the process of explaining the legislator’s intentions. First of all, it is 
necessary to identify the agent who has enacted the law and whose behaviour should 
be examined. As the legislative process is a collective act which involves many different 
actors, the researcher must ask whose aims and beliefs form the basis of explanation. 
However, according to Aarnio, in the context of practical inference this issue has been 
resolved since the prevalent general use of the term “legislator” is not problematic. 
Under this research the parliament, government and relevant ministries in Finland and 
Norway comprise the legislator for each country. This research focuses on the intent of 
the legislator as opposed to other interest groups within the pharmacy sector, 
including public authorities such as the relevant national medicines authority or 
competition authority.12  
The second problem concerns the manner in which the researcher discovers the 
motives of the agent. The motives and aims of individual actors, such as politicians, 
individual public officials or experts engaged in legislative drafting, can have a 
significant impact on the legislative process. However, examining the background of 
individual persons rarely brings to light the concrete aims and the particular problems 
which need to be addressed through legislation. The collective aims of the legislator 
are best explained through social and ideological history. This process needs to take 
into account the social and cultural environment in which the legislator acts, the 
prevalent ideology in civil society, and the basic principles on which the functioning of 
society is based. Here legal research has much to gain from the teachings of social 
science. Thirdly, the researcher needs to identify the concrete aims of the legislator 
within the special problematics of the field which the legislation is regulating.13 
3.3. Rules, Principles and Policies 
The knowledge interest of this research relates to legal principles and their role in the 
pharmacy system in Finland and Norway. Firstly, the research needs to identify the 
applicable legal principles. Secondly, in examining the legislator’s choices particularly 
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within a field where legislation is instrumental in nature, principles need to be 
distinguished from policies. Therefore, it is important to describe the theory regarding 
legal principles used in this research.  
According to positivist legal theory, the scope valid law can be determined on formal 
criteria and is ultimately based on a rule of recognition in the form of institutional 
support. Dworkin finds this kind of definition to be insufficient since it excludes 
principles from the scope of valid law. Dworkin distinguishes between rules and 
principles and has based his distinction on the character of the direction they give. 
Rules are applied in an all-or-nothing manner where either the rule is valid or not. In 
case of conflict between two rules, one rule is valid and the other is not. Principles on 
the other hand provide argumentation in one direction but do not necessitate a 
particular decision. They include a dimension of weight, so in case of conflict between 
two principles one will prevail but the other still retains its validity. Here, Dworkin 
discusses principles in a larger meaning, comprising principles as well as policies as 
opposed to rules. 14 
Tolonen builds upon this distinction between rules on one hand, and principles and 
policies on the other. He distinguishes rules and principles in terms of their validity and 
their relevance. The validity of a rule can be ascertained through the rule of 
recognition. Tolonen however disagrees with Dworkin’s notion of all-or-nothing 
validity. A conflict between two rules can be resolved with use of a principle such as lex 
specialis derogat legi generali where the overridden rule does not lose its validity. 
According to Tolonen the validity of a principle is not tied to a rule of recognition but 
should be identified based on its substance, value or significance. A principle is valid 
due to the fact that it has weight and value in the legal system and that there is 
institutional support for the principle. Tuori finds that in addition to the role of 
institutional support in verifying the validity of principles on this more superficial level, 
the requirement of institutional support also reaches the general principles found in 
deeper structures of law. From this perspective, the requirement of institutional 
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support reflects the sedimentation of principles in the legal system. This is what, 
according to Tuori, gives principles their legal nature.15 
Another aspect in distinguishing rules from principles under Tolonen’s theory is 
relevance. This refers to the scope of application of a norm.  Its overall validity should 
be separated from the question of its applicability in a concrete case. Within the 
defined scope of application of a rule, the decision must necessarily be based on that 
rule: its relevance has an all-or-nothing nature. With principles this is not the case even 
within their scope of application. Furthermore, the weight of a principle is contextual 
and differs with the concrete circumstances in which the principle is applied.16 
Tolonen also discusses the question of conflicts between rules and between principles. 
Conflicts between rules are resolved based on formal criteria regardless of their 
weight, value or substance. Such criteria include for example the principle lex superior 
derogate legi inferiori. Conflicts between principles on the other hand cannot be 
resolved through formal considerations. They are resolved on the basis of the 
significance, value and weight which they are given in the context of the concrete case. 
According to Tolonen, this makes legal principles a parallel phenomenon with moral 
principles. Law can be seen as institutional morality in which the valuation of principles 
is restricted and guided by institutional requirements. Tolonen describes decision-
making based on legal principles as an institutional valuation.17 
Dworkin describes a policy as a “standard that sets out a goal to be reached, generally 
an improvement in some economic, political, or social feature of the community”. For 
Dworkin, the substance of policies is in their aims in relation to society. Also the 
communal nature of policies distinguishes them from principles. A principle on the 
other hand “is a requirement of justice or fairness or some other dimension of 
morality”. Under the rights thesis, arguments of principle intend to establish individual 
rights. This distinguishes principles from policies where arguments are intended to 
establish collective goals. It is the task of the legislator to set social policy goals and in 
this work the legislator is guided by arguments of policy. The rights thesis is built on 
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the idea that a citizen’s rights can only be based on rules and principles. Courts base 
their decisions on rules and principles and arguments of principle are thus 
characteristic to their activity. Dworkin’s view is that rights exist prior to and regardless 
of the actions or decisions of public authorities and they are binding upon courts. 
Therefore, arguments of principle prevail over arguments of policy. However, he also 
finds that policies may be formulated into principles and, on the other hand, principles 
may be adopted as political aims. This may be seen to dilute the difference between 
principles and policies.18 
Tolonen finds that the distinction between principles and policies is important in 
examining the difference between law or justice and social policy and in discussing 
increased goal-orientation within law. In Tolonen’s view, the rights thesis categorizes 
only certain kind of legal principles as legal principles. The rights thesis does not 
sufficiently consider the relationship between interventionist legislation and self-
regulating or reflexive legal mechanisms within the legal system. The amount of open 
and elastic legislative mechanisms is increasing, and, while their substance may 
depend on arguments of social policies and aims, in practice such mechanisms can 
establish rights to individual citizens.  
In addition to the rights thesis, Tolonen finds elements of a thesis of universalizability 
in Dworkin’s views regarding principles and policies and he builds upon this in his 
distinction between principles and policies. Under Tolonen’s postulate of 
universalizability, “cases which are similar in the relevant manner shall be treated in a 
similar manner”19. Principles include a different kind of requirement of 
universalizability than policies. For example, common goods such as public health will 
have a different role within the legal system if it is treated as a requirement of social 
policy than if it is treated as a legal principle. Furthermore, from the perspective of the 
ratio of law, an argument of policy does not have the same status as a legal principle. 
Tolonen bases his distinction on the idea that the requirement of universalizability 
applies to rules and principles but not to policies. The postulate of coherence and 
consistence specifies the institutional criteria for applying the principle. Tolonen finds 
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that neither his nor Dworkin’s distinction of rights and policies is absolute or 
qualitative, but rather relative. Whether legal requirements of a goal-oriented nature 
are legal principles or policies cannot be derived from their substance. Such 
distinctions are relative and are resolved by the legal system in the form of an 
institutional valuation. Arguments of goal have an impact in the legal system but are 
restricted by certain institutional requirements.20 
The distinction between rules, on one hand, and principles and policies on the other 
ultimately deals with the relationship between law and morality. The question of 
distinguishing between rules and principles on one hand, and policies on the other is 
related to the relationship between law and politics. The way in which the distinction 
between principles and policies is applied in different sections of society changes in 
pace with social development.21  
Tolonen also discusses the role of principles in the legal system. He describes law as a 
substantive system in which two basic ideas are central. The first idea relates to the 
consistence and coherence within the system and to conflict as their opposite 
phenomenon. Secondly, the development of the legal system ties conflicts to the 
development of society. Tolonen sees the legal system as one which is conflicted in 
nature and which simultaneously, by its nature, eliminates its conflicts, that is it strives 
for consistence and coherence. From the substantive aspect of the legal system, 
conflict can be described as a state of anomy. Law as a substantive system resolves 
and removes conflicts on different levels. Conflicts can be resolved on the level of 
rules, principles or theories. Conflicts between rules are resolved on the level of 
principles whereas conflicts of principles are resolved on the level of theories. Theories 
are part of the general principles of law and they are material in nature. According to 
Tuori, legal theories group legal concepts into networks and organize legal principles 
into prima facie orders of priority. Legal theories include normative justification for the 
legal institution under discussion. This deeper justification guides the manner in which 
the prima facie order of principles is defined and legal concepts are grouped. Theories 
also include their own understanding of the social relations which legal norms 
regulate. Under the substantive aspect law has an essentially wider scope than from 
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the perspective of legal formalism. The general principles of law and particularly legal 
principles occupy an essential place in the legal system. Legal principles form the 
central substantive conception of the legal order and remove anomy and conflicts 
between legal norms.22  
According to Tolonen, law regulates its own change with use of universalizable norms. 
Law includes its own general principles regarding the criteria under which legal change 
is possible. These general principles form the doctrine of the sources of law. It is 
notable that the legal system includes very few written rules regarding sources of law 
and that this doctrine relies mainly on principles. In regulating change, the conflicting 
requirements between predictability and elasticity need to be consolidated. The 
doctrine of the sources of law defines the role which policy arguments have in the 
legal system and in changing the law. For example, the prevalent doctrine in Nordic 
countries recognizes real arguments as a source of law and applies a special concept of 
institutional universalizability to them.23  
Tuori discusses the role of sedimentation in relation to the development of law. 
Sedimentation begins with the normative material produced by legislative and judicial 
bodies in their decision-making. A legal norm on a more superficial level of law can 
become embedded in the deeper structures of law over time for example through 
court practice or jurisprudence. General principles of law embedded in the sediments 
of the legal system have an influence on the norms employed on the surface and the 
manner in which they are applied. Furthermore, legal principles are also horizontally 
connected with other norms functioning on the same level, and general principles of 
law have constant interaction with the ethical values and moral principles prevalent in 
society. Legal principles are applied in the context of the case at hand and are thus 
connected with the facts and circumstances of the case, that is, with extra-legal 
factors. According to Tuori, the development of the legal system is ultimately 
determined by external factors. However, the impact of these factors is refracted 
through the internal mechanisms of the legal system. The ratio of law and the 
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requirement of coherence define how the legal system responds to social 
development – how the legal order can change as society changes.24 
3.4. Comparative Law 
This work utilizes the comparative method. Sections 5.2 and 7 provide descriptive 
overviews of the pharmacy systems of Finland and Norway respectively. These two 
systems are the objects of comparative analysis aiming at identifying the rights, 
principles and policies which form the basis for regulating pharmaceutical distribution. 
Comparative law can be a difficult science to approach. Therefore, before describing 
the methodological choices of comparison, I have shortly addressed the field of 
comparative law in more general terms.  
3.4.1. Comparative Law as a Science 
Zweigert and Kötz on begin their definition of comparative law as “intellectual activity 
with law as its object and comparison as its process” and highlight the role of 
internationalism in distinguishing comparative law “from what lawyers normally do” 
within their national legal systems.25 Bogdan on the other hand has constructed a 
definition of comparative law for the purpose of providing an overview of the field for 
students of law. According to his definition of the field, comparative law includes: 
“the comparison of different legal systems with the purpose of 
ascertaining their similarities and differences; 
working with similarities and differences that have been ascertained, for 
instance explaining their origin, evaluating of the solutions utilized in the 
different legal systems, grouping of legal systems into families of law, or 
searching for the common core of the legal systems; and 
the treatment of the methodological problems which arise in connection 
with these tasks, including methodological problems connected to the 
study of foreign law.”26 
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The above definition works from multiple perspectives. Firstly, it can be viewed as an 
attempt to summarize the essential elements of comparative law as a science. 
Secondly, Bogdan’s definition lists various types of research which can be grouped 
under the heading “comparative law”. Finally, it identifies three levels of comparative 
law, where the first level is descriptive comparison and the second level includes 
analysis of the findings in a greater context. These parts of comparative law can be 
described as comparative research. The third level works with problems within the 
comparative method itself. This approach is called comparative law theory27. 
In defining comparative law, Husa groups comparative law together with social 
science. He also emphasises the role of comparative law as a cross-border exercise, 
which provides a reconstruction of a foreign system and thus enables dialogue 
between legal systems. It is characteristic for the exercise of comparative law to be 
international and to strive to free oneself from the constraints of one’s own legal 
system. As national legal systems have not been insulated from each other, it is clear 
that there is added informational value to be obtained through cross-border 
comparison: Through comparative law researches can understand their national legal 
system better as well as draw inspiration from foreign legal systems in finding model 
solutions to problems arising in the national legal system.28 
In defining comparative law, it can be useful to coin an example of what it is not. 
According to Husa, the examination of foreign law is useless and without purpose from 
the perspective of comparative law if it is left separate of the knowledge interest of 
the research and if it does not serve the knowledge interest. In order to avoid the 
pitfall of such “ornamental” or “decorative” law comparison, I have outlined the 
interest and method of comparison used in this research in the following sections.29 
3.4.2. Uses of Comparative Law 
Comparative law can be used for the following purposes. These uses of comparative 
law, not to be understood as exhaustive, are general education for lawyers, 
understanding of one’s own legal system, construction in interpretation of national 
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rules, working de lege ferenda, harmonization and unification of laws, working de lege 
lata, public international law, private international law and international penal law, 
legal theory, pedagogical purposes and other uses such as legal history research, law 
dictionaries and sociology of law.30 
Comparative research has also been carried out in the past in order to discover the 
universal principles of law. According to Husa, a certain element of universalism still 
exists within comparative law as it aims at obtaining general knowledge of law which is 
by nature less bound to the state than national legal science. The findings of legal 
comparison can be utilised for deepening and improving normative argumentation but 
as such the knowledge interest of comparative law is not normative in the manner of 
the doctrinal study of law.31 
This research utilizes the comparative method for two of the above purposes. Firstly, 
this work has elements of working de lege ferenda, in that it aims at providing findings 
which can be useful for the legislator. Secondly, the research is carried out in order to 
understand factors which work in the background of regulation concerning medicinal 
products in Finland and Norway. Thus, besides obtaining a better understanding the 
researcher’s own legal system, the work aims at explaining and assessing the reasons 
behind the similarities and differences of the two systems. Reflecting these aims with 
the research paradigm, that there are certain fundamental human and social rights 
regarding health which bind the legislator, one can also perceive some sense of 
universalism in this research. If the idea of this sense of universalism related to health 
law were to be excluded altogether, this research could just as well be carried out in 
Finnish from a purely national perspective. 
3.4.3. Interests of Comparison 
Before carrying out law comparison, it is important to define the basic knowledge 
interests which the comparison is intended to serve. After this, the actual methods of 
comparison need to be established. 
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This research has a practical-theoretical interest as it aims at producing findings which 
can be useful for legislative drafting or policy through increasing the informational 
basis regarding the research topic. The use of doctrinal study of law and more 
specifically of systemisation, as described above in section 3.2 supports and is also 
evidence of the practical interest of comparison. In contrast to the integrative 
approach, this research does not examine opportunities for the harmonisation of laws. 
Another alternative to the practical-theoretical interest would be the contradictive 
approach which works toward the distinction of different legal systems and cultures 
from each other.32  
3.4.4. Technical Methodological Choices 
In light of the research paradigm and research objective, I have made a number of 
technical methodological choices before carrying out comparison. In most comparative 
research the method rarely represents a pure version of any particular technical 
choice. Thus, at times the comparative process includes elements of both 
methodological counterparts. However, the choices outlined below emphasise the 
overall focus of the research. 
In choosing the research objective, I made a choice between the horizontal and the 
vertical method of comparison. In the vertical method, the comparison is carried out 
between legal systems which are on a different level in the scale of national-
supranational law, for example between international law, EU law and national law. 
However, this work represents the more common horizontal method of comparison in 
which both legal systems are national and thus at the same level in the 
abovementioned scale.33 
The subject area under research is related to a concrete and limited activity within 
society, that is, distribution of medicinal products, which means that the comparative 
method used can be described as microcomparison. Research on the micro level 
usually deals with individual legal rules or with individual institutions within a legal 
system. In contrast, macrocomparison works on a greater level of abstraction. In 
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macro research the aim is to understand foreign legal systems and legal cultures 
instead of examining solutions provided for concrete problems in different legal 
systems.34 
The legal systems chosen for this research are Finland and Norway which are both part 
of the Nordic legal culture. The reasons for this choice are manifold. Firstly, as a Finnish 
student of law I am in a favourable position to examine the Finnish legal system. 
However, this can also be a challenge when carrying out law comparison as I am also 
part of the social reality which I am examining. It is not uncommon for lawyers to 
consider their own legal system to be superior to that of others and thus they can have 
an ethnocentric approach to examining foreign systems. I have taken this factor into 
account and at least attempted to eliminate any ethnocentrism from the comparative 
process. 
As the research paradigm is related to human rights and the legislator’s aims, the 
research needs to be carried out on a deeper level of the legal system than on 
individual written rules. Thus, instead of attempting to research many different legal 
systems by way of multilateral comparison, I have chosen to conduct bilateral 
comparison. This allows a deeper examination of factors working in the background of 
legislative acts. In multilateral comparison the research resources would in this case 
only allow a surface glance at the matter.35 Furthermore, the knowledge interest of 
this research is sufficiently served through bilateral comparison. 
The main reason why I have chosen Norway as the second subject of comparison is the 
manner in which the Norwegian pharmacy system has developed in the past decades. 
In short, until 2001 the pharmacy system and the functioning of pharmacies were fairly 
similar in Norway and in Finland. However, in 2001 Norway introduced a law reform 
regarding pharmaceutical distribution and the functioning of pharmacies, whereas the 
Finnish legislation did not undergo a significant reform. Both systems have been 
amended partially in a number of ways in the past years and many of the amendments 
have followed similar trends in the field.36 Thus, Finland and Norway provide fruitful 
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grounds for comparison as the similarities in the background of the pharmacy systems 
can be reflected upon the different legislative choices made at the end of the 1990s.  
Furthermore, the two legal systems both fall within the Nordic legal culture. As my 
knowledge interest is to find out the intention of the legislator and to understand the 
human rights factors in the background of legislation, research within one family of 
legal cultures is a practical choice. Comparison between different legal cultures would 
be a better choice for example in researching a legal problem which has not been 
regulated in written legal rules in some countries or in macrocomparison. 
The comparison will focus on the recent preparatory background of the current 
legislation regarding pharmaceutical distribution in Finland and Norway. The focus of 
the research is on current matters and recent developments instead of historical 
matters and thus it can be described as transverse comparison. The methodological 
counterpart for transverse comparison is longitudinal comparison which examines the 
historical development of a legal system or legal institution or the way a problem has 
been addressed throughout history.37 
3.4.5. Theoretical Methodological Choices 
The theoretical emphasis of legal comparison depends on the knowledge interest and 
the nature of the subject area under research. After familiarising oneself with the 
source material and the legal culture under study, the comparatist will define the 
research objectives in more detail and make choices regarding the general theoretical 
framework of research. Husa has identified four alternative basic strategies for 
comparative research: functional comparison, structural comparison, system 
comparison and critical comparison.38 
The methodological approach chosen for this research is based on functionalism39 as 
defined below. Functionalist comparison, represented by Zweigert and Kötz, is based 
on the idea that “the legal system of every society faces essentially the same 
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problems, and solves these problems by quite different means though very often with 
similar results”40. Thus, the functionalist approach focuses on examining the legal 
institutions which have been formed as responses to the same problem in different 
legal systems. Through this approach the researcher is more able to eliminate their 
own preconceptions regarding foreign law and the legal institution under review view. 
Furthermore, the functionalist approach provides a means to view one’s own legal 
system from the outside. This provides a kind of partial objectivity as researchers can 
treat each legal system in the same manner despite of national backgrounds.41 
The functional method utilises the concept of functional equivalents in order to 
establish comparability between different legal systems: For instance, if system s1 has 
introduced the institution i1 as a response to problem p and system s2 has introduced 
the institution i2 as a solution to the same problem p, there is a functional equivalency 
between the institutions in those systems. The functions for the institutions in those 
systems are similar even if the legal institutions and the legal systems as such are 
dissimilar. According to Michaels, functionalism views an institution within a legal 
system as “a possible but not necessary response to a problem”, which explains the 
differences between legal systems also in the face of universal problems.42 
The common denominator for the legal institutions to be examined in this work is their 
function as defined in chapter 4.4.4. I have determined the substantial focus of the 
research with the use of functional equivalence relating to the regulation of 
pharmacies and medicinal products. However, as the two legal systems are within the 
same family of legal culture and at a similar stage of development, the process of 
defining this focus has been relatively unproblematic. In this case the chosen focus 
could have been much the same with very little consideration for method: The 
relevant legislation regarding pharmaceutical distribution is readily available in both 
systems for anyone with knowledge of Finnish and Norwegian. Nevertheless, the 
process used in this research is, if not entirely based on functional considerations, at 
least symptomatic of functionalism. 
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The role of functionalism is more evident in the comparison carried out in this 
research. For the purpose of analysing of the legislator’s aims and intentions, I have 
constructed a number of universal problems in chapter 4.4.4 which I use as tertia 
comparationis against which two legal systems can be compared. This comparison is 
based on the notion that the legal institutions under comparison are responses to 
societal needs which can be identified with reference to other possible responses 
which are functionally equivalent with them. With use of a problem as tertium 
comparationis I will be able to describe and explain differences and similarities of the 
Finnish and Norwegian responses.43 
This research does not apply a praesumptio similitudinis as understood in discussions 
regarding comparative law44. In functionalism two systems s1 and s2 are not assumed 
to be similar as such, nor are the legal institutions i1 and i2. However, for functionally 
equivalent institutions within legal systems, the institutions are assumed to be similar 
in terms of function as they respond to the same problem. However, while they are 
similar in this regard, they can still have many other similarities and differences. This 
research aims at discovering both and does so by examining the legal institutions of 
Finland and Norway through the system of functionalism. In this research I have 
utilised the functionalist systemisation of problems, responses and functions as 
described above. This allows the construction of a corresponding system from the 
findings and thus to better understand the underlying problems and aims within 
Finnish and Norwegian pharmacy legislation.45 
In my approach to comparing pharmacy legislation I examine preparatory works and 
the legislator’s intent.  I have described the exercise of discovering the legislator’s 
intent as finalistic explanation as defined by Aarnio. Michaels has discussed the 
element of finalism in functionalist comparison. He describes the Aristotelian 
understanding of the notion of function in which the purpose of a thing, causa finalis, 
is considered inherent in its nature. According to Michaels, legal comparatists have 
employed this idea in the sense that they have seen the different solutions found for 
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common problems as “contingent in their form but none the less required by the 
nature of the problem”. The function of an institution has since been separated from 
its cause or origin as well as from its essence in legal research. Under this research, my 
comparison employs elements from both the functionalist method and finalistic 
explanation. However, despite my interest in why the legislator has chosen a particular 
institution as the solution for a problem, I do not treat the function of the institutions 
under comparison as inherent in their nature.46 
3.4.6. Linguistic Considerations 
Language is a vital factor for legal comparison. The source material for this work is 
mostly in Finnish and in Norwegian. This work has been written in English in order to 
enable readers representing both legal systems to benefit from its findings. The aim of 
this work is to identify factors which function in the background of the legislator’s 
work. As many of these factors are related to international treaties and human rights 
considerations, the findings can be of use to readers from outside of Finland and 
Norway as well. Furthermore, as stated above, one of the principal aims for this work 
is to provide a piece of comparative research which any national legislator could 
benefit from in its work. It serves this aim to make the research outcome available in 
the current lingua franca of legal research, in English. 
When conducting comparative research, the question of translation should be taken 
into account. When describing and analysing a foreign legal system in English, it is 
important to understand the meaning which each term may have in each language. 
First of all, the researcher must reflect upon the meaning of legal language in the 
context of the legal culture which she is examining. Secondly, the terms need to be 
translated accurately and made understandable for the reader in the context of the 
language used to present the findings. Additionally, I have adopted terms which have 
an established use in EU law for use in this research when suitable. 
The professional vocabulary in the pharmacy field has been developed from the same 
scientific premises internationally. Thus, translating terms from Finnish or Norwegian 
to English is mostly unproblematic. There are, however, some characteristic features in 
the pharmacy system of both countries, which do not have accurate counterparts in 
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the English language. In such cases, I will attempt to describe the terms without the 
use of professional terms. 
Under this research I will provide a definition of a medicinal product as opposed to 
non-medicinal products under the EU regulatory framework. I will also use the terms 
“pharmaceuticals” or “pharmaceutical products” interchangeably with the meaning 
“medicinal products”. Similarly, I will use the more everyday terms “prescription drug” 
and “over the counter drug” when discussing medicinal products subject to 
prescription and ones distributed without a prescription respectively. 
3.5. Source Materials 
This work utilises primary sources such as legislative acts and regulations as well as 
decisions and guidelines of public authorities in Finland and Norway. In researching the 
aims and intentions of the legislator, the comparison will rely on preparatory 
materials, travaux préparatoires, of legislative acts to a high degree. 
Eckhoff discusses the significance and weight of different sources of travaux 
préparatoires in interpretation based on the instance which has produced the 
material. It could be argued that the greatest weight should be given to utterances 
from instances closest to the actual enactment of the relevant piece of legislation, for 
example on the opinions of parliamentary committees discussing the law proposal. 
However, Eckhoff emphasises the role of professional and expert opinions in drafting 
acts of legislation. The underlying legal and societal reasons for legislative choices can 
be found primarily in the opinions adopted by the instance which has actually drafted 
the law proposal. These choices are based on the professional and expert discussions 
and opinions expressed in preparatory committee as well as in policies outlined within 
the relevant ministry which is ultimately responsible for drafting the text of the law. 
Therefore, this research focuses on law proposals and preparatory memoranda as the 
principal source of information regarding the reasons for which a legislative act has 
been enacted.47 
Some works of legal research in the field of health law, social law, competition law and 
intellectual property law touch upon the topic of pharmaceutical distribution. 
                                                     
47
 Eckhoff, Torstein & Helgesen, Jan E., Rettskildelære p. 73–74. 
24 
 
However, legal research has produced very little literature regarding the regulatory 
framework of pharmacies as a field of business. Thus, the use of secondary sources is 
limited to some legal literature and to articles and reports regarding the functioning of 
the pharmacy system by state authorities, such as the Finnish Competition Authority, 
or by interest groups, such as the Norwegian Pharmacy Association. Pharmacy systems 
have been examined in economic and pharmaceutical research as well. I have utilised a 
number of economic reviews in this work. However, pharmaceutical research 
regarding pharmacies is more focused on concrete practices regarding the handling of 
drugs or the treatment for patients in pharmacies. Such research does not serve the 
knowledge interest at hand. 
In developing the research method, I have mainly used Finnish works regarding legal 
theory. However, some of the works regarding legal theory and comparative law are 
international and some are Norwegian. 
4. Background for Comparison 
4.1. Nordic Legal Culture 
This research examines the laws of Finland and Norway relating to the pharmacy 
sector within the context of the Nordic legal tradition. 
Finland and Norway are both part of the Nordic family of law which is a special legal 
family within Civil Law. Nordic countries, which comprise Denmark, Finland, Iceland, 
Norway and Sweden, have close cultural ties and they have developed historically, 
politically and economically in a similar manner. Finland was part of the Swedish 
Empire from the thirteenth century to 1809 when it became an autonomous Grand 
Duchy within the Russian state. Finland gained independence from Russia at the end of 
191748. Norway was under the control of the Danish crown until 1814 when it became 
part of Sweden. Norway became independent in 1905.49 
Nordic laws were historically based on old Germanic law with local variations in each 
country. Customary law, applied by laymen or elders, had a significant role in local 
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communities and legal life during the Middle Ages. The impact of the Church was 
significant as customary laws were written down. Furthermore, the role of the king 
grew both in Norway and in Sweden. In both countries, the first written laws were city 
and town laws.50 
In the 17th century, the idea of the nation state became more prominent. The role of 
the central administration and higher courts became significant in the development of 
the law. The influence of civil law is prominent in the Nordic countries, as particularly 
in the seventeenth century many Nordic legal scholars gained their education in 
protestant Germany. This brought with it the influence of Roman law. However, its 
impact was not as strong in the Nordics as in Continental Europe. Roman law was used 
for systemization of domestic city laws and customary law and to resolve deficiencies 
in the traditional local practices especially within commercial law, rather than as the 
primary source of law. Both within the Swedish Empire and in Denmark-Norway the 
centralization of power to the state led to the creation of comprehensive codes at the 
turn of the eighteenth century. These codifications were influenced by Roman law but 
were tied to the traditions of old law in construction, style and diction. In Nordic legal 
life Roman law was used an applied through a filter of rationality and practicality. High 
courts used a variety of legal sources and their decisions derogated from written law 
relatively often, thus influencing the development of law significantly. In the late 17th 
century, the influence of natural law highlighted the role of the state and of written 
law as the secular embodiment of universal law based on the will of God. The 
sovereignty and power of the state was justified through the idea that the state was in 
the best position to ensure the fulfilment of citizens’ freedoms and rights and the 
interests of citizens were assumed to be in line with the interests of the state.51   
In addition to using arguments regarding natural law, legal scholars began employing 
ideas which could be seen as the first steps toward positivism. Simultaneously, 
decision-making in courts started to rely more on written law. Inspired by the French 
Revolution, Sweden and Denmark both modernized their codes in the early 1800s. 
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However, after Russia’s annexation of Finland, the Finnish legal life underwent a 
stagnant period until the 1850s and the progressive approach taken by Czar Alexander 
II. However, under Russian rule, Finnish autonomy was embodied in the Finnish senate 
in which the role of lawyers became significant. During the late 1800s significant law 
reforms were introduced in nearly all areas of law in Finland. Universities began 
educating lawyers for purposes of the public administration and courts. The legal 
profession developed into its own distinct field during the 18th and 19th centuries. The 
role of legal positivism in Finland was emphasised through the passive struggle against 
periods of Russian oppression at the turn of the 20th century. Under positivist 
thinking, written law took a supreme position in the hierarchy of legal sources.52  
The Nordic legal systems are characterized by an underlying positivist tendency even 
today. Throughout the late nineteenth century and early twentieth century Sweden, 
Norway, Denmark and Iceland engaged in significant legislative cooperation and 
unification of commercial law. The principles of parliamentarianism and democracy 
were highlighted in the Nordic countries. When Norway became independent, its new 
constitution was based on Montesquieu’s separation of powers. After gaining 
independence, Finland adopted results of Nordic cooperation in its legislation and 
joined the cooperation. For the first half of the twentieth century Finnish legal life was 
more conservative than in other Nordic countries. However, Finland joined the group 
of Scandinavian welfare states through rapid societal change and economic 
development after World War II.53 
As small nations on the northern fringe of Europe, the Nordic countries had much to 
gain from cooperation. Nordic countries benefited from reduced barriers to trade due 
to unification of laws. Due to sharing and comparing experiences, the resulting 
legislation was of good quality. The Nordic style of legal theory and legislative drafting, 
while open to influence from Continental Europe, has been reasonable and pragmatic 
in its adoption of external ideas and trends. Particularly during the 1930s – 1950s, 
Nordic legal scholars criticized positivism. The school of Scandinavian realism 
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promoted the use of practical and real arguments in legal decision-making over 
abstraction and construction. Later on, also the analytic study of law challenged 
positivism and the jurisprudence of concepts. Thus, there has been a smaller tendency 
towards the construction of ambitiously large theoretical systems. For example, 
instead of carrying out immense codification projects, the legal order in Nordic 
countries consists of individual acts of legislation on more specified topics.54  
4.2. Sources of Law 
Since Finland and Norway are part of the Nordic legal culture under the civil law family, 
both legal systems rely mainly on statutory law. The constitution, other legislative acts 
and lower level government regulations or decrees55 are the primary sources of law. 
The hierarchy of national statutes, beginning with the highest, is: Constitution, act of 
law, government decree or regulation, decision of the Council of Ministers, decision of 
a Ministry and other authoritative instructions. Written sources of law are first and 
foremost interpreted based on the text of the statute, that is, its literal meaning. 
However, as more and more domains of society and life become regulated by 
legislation, written statutes have become more open and elastic: It is not feasible nor 
does it serve the purposes of the rule of law to regulate all contingencies in a casuistic 
manner. Open and elastic norms allow for more consideration and interpretation, 
which requires use of other sources of law. Their use is also necessary due to the 
fragmented nature of legal norms.56 
According to Aarnio, the classification of sources of law in relation to their binding 
force first presented by Aleksander Peczenik is the basis of the doctrine of source of 
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law in Nordic countries. The classification demonstrates the weight given to different 
sources of law as legal arguments in interpretation.57 
The first category, strongly binding sources of law, includes transnational legal sources 
which have priority over national legislation or which have been implemented in the 
national legal order, fundamental rights of the constitution, statutes and decrees or 
regulations and national custom. A decision which ignores a strongly binding source of 
law is illegal and should be overruled in appeal. Within this category, transnational law 
and the constitution are strictly binding. Deviation from statutes and national custom 
is possible only in case there are special grounds for bypassing the relevant strongly 
binding source of law.58 
The second classification is weakly binding sources of law. This category includes the 
intention of the legislator and precedents. In practice the strongest indicators of the 
legislator’s intent are found in preparatory works, travaux préparatoires, such as 
government proposals, reports of preparatory committees and decisions of 
parliamentary committees. Precedents have a much smaller role in the Nordic legal 
culture than for instance in common law. However, public decisions of the Supreme 
Court and Supreme Administrative Court have weakly binding normative force. Also 
decisions of certain appellate courts from which there is no possibility of recourse to a 
higher court can have precedential value.59 
Lastly, Peczenik included the following sources of law in the group of permitted 
sources of law: practical arguments, ethical and moral arguments, general legal 
principles, prevailing opinion within jurisprudence and comparative arguments. These 
permitted sources of law are important as further argumentation for and against 
different alternatives of interpretation when other sources of law do not provide 
sufficient support for either option. Permitted sources of law are employed through 
consequential deliberation, whereby the evaluation is based on the possible results of 
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alternative conclusions. The interpreter can assess under which conclusion applicable 
legal principles are fulfilled to a greater extent. The options can also be weighed based 
on which of them yields the best moral or practical results.60  
Aarnio also categorizes sources of law as authoritative and substantial. The former 
refers to the institutional significance and the latter to the content of the source of 
law. Under this categorization, written law, travaux préparatoires, court decisions and 
jurisprudence are authoritative sources of law. They can be applied on the basis of 
their authoritative status. Custom, legal principles, moral and real arguments on the 
other hand draw their argumentative persuasiveness from their substance and 
therefore they alone cannot be applied as the basis of legal argumentation – their role 
is to work as arguments pro and contra authoritative arguments.61 
Tolonen however finds that the role of principles within the sources of law is more 
complex than as presented by Peczenik and Aarnio. From a formal point of view, the 
relevance of legal principles in the legal system is weak. Rules are the primary factor 
which maintains and defines the contents of the law whereas principles have a 
secondary position. This view is prevalent in legal positivism. On the other hand, from 
the perspective of the substantive aspect, legal principles are part of the substance of 
the legal order and they are binding. The relevance of legal principles within the legal 
system has been described in more detail in chapter 3.3 which is also how this 
research treats legal principles. However, as legal positivism is part of the Nordic legal 
culture, the categorizations presented here are useful for understanding the basics of 
the doctrine of sources of law in Finland and Norway.62 
In Finland, EU law has primacy over national legislation. The EAA, EC and EU treaties 
have been incorporated with a qualified majority as an exception to the Constitution 
and thus have supremacy over national acts of law.63 In Norway, the EAA treaty as well 
as other bilateral EU treaties have been implemented in the same manner as other 
international treaties as described in the following chapter. 
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4.3. Fundamental and Human Rights in the Legal System 
This chapter examines the role of fundamental and human rights Finland and Norway. 
The former are rights guaranteed under the constitution and latter are provided for in 
international human rights treaties which the state has ratified. Nordic countries 
implement international treaty provisions in a fairly similar manner to each other. Also, 
Nordic countries traditionally share similar foundational values and a common 
constitutional conception which includes the following elements: parliamentary 
system, legislative supremacy, consensual democracy, limited relevance of judicial 
review, elements of constitutionalism, constitutional conformity interpretation, duty 
to ensure fundamental rights on legislature rather than on courts. One example of 
differences between Finland and Norway is judicial review. Nether country has a 
constitutional court. In Finland, constitutional conformity of legislative acts is reviewed 
a priori by the special parliamentary standing committee, Committee for Constitutional 
Law (Perustuslakivaliokunta), whereas the role of the Supreme Court in Norway in 
judicial review is greater than in other Nordic countries.64 
The following chapters outline how international human rights treaties have been 
implemented and how fundamental rights are applied in the Finnish and Norwegian 
legal system. 
4.3.1. Finland 
Traditionally Finland has employed the dualistic model in defining the relationship 
between domestic and international law. Thus, the main rule is that international 
provisions under international treaties need to be included as part of national law. 
Ratification of international treaties requires approval from the Finnish Parliament 
(Constitution of Finland (Suomen perustuslaki 731/1999, CoF) CoF 94 §, 95 §)). The 
actual implementation of treaty provisions on the other hand can be carried out in 
several ways.65 
Firstly, international treaties can be incorporated into the Finnish legal system through 
an act of Parliament or a government decree stating that the international treaty and 
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its provisions are in force in Finland. According to Scheinin, wide use of the 
incorporation method suggests a kind of “de facto monism”. Under this method, the 
provisions of the treaty will have the same position in the hierarchy of laws as the 
ratifying act or decree. Incorporation has been the most common method of 
implementing international treaty provisions in the Finnish legal order66. The second 
method is implementation through transformation. This entails enacting new 
legislation or amendments to existing legislation in order to bring domestic law to be in 
line with international treaty provisions. Thirdly, treaties can be implemented by 
reference. Under this method, special clauses in domestic legislation state that 
international treaties need to be taken into account, creating a domain within the 
domestic legal order which is in practice monistic.67 
In Finland, a rule of presumption is applied to cases where national legislation and 
international treaties have conflicting interpretations. Courts are allowed and required 
to assume that in enacting legislation the Parliament had no intention to derogate 
from international treaty obligations unless an intention to derogate from them is 
expressly stated and thus interpret domestic statutes in line with international 
treaties.68  
Also international human rights treaties need to be implemented – they do not have a 
self-executing status in Finland. Most international human rights treaties have been 
incorporated through an act of Parliament and can be applied directly by domestic 
courts and public authorities. The European Social Charter (ESC)69 and the European 
Convention on Human Rights (ECHR)70 were both implemented in this manner in 
Finland in 1990. Prior to the constitutional reform in 2000, pursuant to section 92 of 
the Finnish Constitution Act (Suomen hallitusmuoto 94/1919) judges and public 
authorities had a duty not to apply government decrees which are in conflict with the 
Constitution or acts of Parliament. The corresponding provision can be found in 
section 107 of the Finnish Constitution. In practice this meant an obligation to 
interpret lower-level statutes in line with the constitution and acts of Parliament. 
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However, this provision did not apply in relation to international human rights treaties 
which had been implemented only by government decree due to their programmatic 
nature, such as the UN International Covenant on Economic, Social and Cultural 
Rights71. However, the matter has been resolved under the new Finnish Constitution.72 
In 2000, the Finnish Constitution was enacted after a reform process combining the 
four acts of law which until then had constitutional status73. The constitutional reform 
built on the constitutional tradition of the country so far and did not constitute a 
drastic change in the Finnish constitution and legal life. However, it modernized the 
constitution and increased parliamentarianism. The new Constitution of Finland 
included a catalogue of fundamental rights which had been included in the 
Constitution Act in 1995 in connection with Finland’s accession to the EEA and EU 
membership. The catalogue of fundamental rights reflected international human rights 
treaties and included civil rights and freedoms as well as social human rights. In 
addition to cataloguing fundamental rights, the 1995 reform aimed at emphasizing the 
obligation of courts and public authorities to apply fundamental rights norms in their 
decision-making.74 
In connection with the 1995 fundamental rights reform, the Committee for 
Constitutional Law discussed the application of fundamental rights and their position 
in the hierarchy of laws. The memorandum of the Committee (25/1993) has since 
defined the interpretation of fundamental rights and the manner in which they are 
binding upon the legislator in the legislative process. The Committee for Constitutional 
Law reviews whether proposed acts of legislation conform with the constitution and 
what their relationship is with international human rights treaties (CoF 74 §). In 
connection with the statement in Section 1 of the Constitution that “Finland 
participates in international cooperation for the protection of peace and human 
rights”, a priori judicial review has made the enactment of legislation in conflict with 
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human rights impossible in practice. In its recommendations, the Committee also 
emphasized interpretation of Finnish legislation in favor of fundamental and human 
rights. This gives international human rights a limited status of lex superior in the 
hierarchy of laws. In addition to the Committee for Constitutional Law, the 
Parliamentary Ombudsman gives statements on the application of international 
human rights in the Finnish legal systems and has for example applied certain 
international treaties such as the ECHR already before its ratification in Finland.75 
The new Constitution includes the prohibition of delegating the competence to decide 
on measures which restrict fundamental rights with use of a decree or other decision 
which is on a lower level of hierarchy than an act of Parliament (CoF 80 §). Since then 
the legislative process has included a review of whether the proposed law includes 
such a delegation. Section 22 of the Finnish Constitution brings human rights on the 
same level with fundamental rights: “The public authorities shall guarantee the 
observance of basic rights and liberties and human rights.”76 
Finland’s membership in the European Union is provided for in Section 1.3 of the 
Finnish Constitution and EU law is directly applicable in Finland and has precedence 
over domestic legislation. This means that the precedents of the Court of Justice of the 
European Union (CJEU) as well as the special doctrine of sources of law within EU law 
are applied legal interpretation. The EU Charter of Fundamental Rights77 also has direct 
application in Finland. Through the accession of the EU to the ECHR under the Lisbon 
Treaty78 the human rights under the ECHR became directly applicable via EU law 
(Lisbon Treaty Art. 6.2).79 
4.3.2. Norway 
Like Finland, in its implementation of international treaties Norway follows the 
dualistic model. Therefore, in order for public authorities and courts to be bound by 
provisions of international human rights treaties in their decision-making, the 
provisions need to be implemented as part of the Norwegian legal order. Also, the rule 
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of presumption is applied in the interpretation of domestic legislation by courts, and 
thus interpretation in conformity with international treaties is preferred. Domestic 
sources of law must include clear evidence that the legislator in fact intended to 
derogate from treaty provisions in order to allow an interpretation which conflicts with 
the treaty.80 
The methods of implementation used in Norway include incorporation, reference and 
transformation. Similarly to the Finnish system, the Constitution of Norway (CoN) 
(Kongeriket Norges Grunnlov, 17. mai 1814) requires approval from the Parliament for 
international treaties (CoN 26 §). Through the method of reference, some treaties 
enjoy direct applicability within specified spheres of the domestic legal order. 
International treaties incorporated into Norwegian law by an act of Parliament can be 
considered an order directed at public authorities to observe the provisions of the 
treaties in their activities and decision-making.81 
In 1999, Norway incorporated the ECHR, the 1966 United Nations International 
Covenant on Civil and Political Rights82 and the 1966 United Nations International 
Covenant on Economic, Social and Cultural Rights as part of Norwegian law in the 
Norwegian Human Rights Act (Lov om styrking av menneskerettighetenes stilling i 
norsk rett 21. mai 1999 nr. 30 (menneskerettsloven)). The preparatory committee of 
the Human Rights Act discussed the position of international human rights in the 
Norwegian legal system and proposed that the international human rights treaties 
which Norway has ratified should be incorporated by act of Parliament and the text of 
the treaty should be included in original form and as a translation in the act. The 
committee also proposed the inclusion of a direct statement regarding human rights in 
the Norwegian Constitution. Such a statement was introduced and is now included in 
Article 92 of the Norwegian Constitution.83 
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Article 92 of the Norwegian Constitution requires that courts and public authorities 
respect and ensure fundamental and human rights “as they are expressed in the 
Constitution and in the treaties concerning human rights that are binding for Norway”. 
This provision has the role of a rule of interpretation for courts but also works as a 
requirement for the legislator to consider the requirements of human rights and 
promote them through legislation. As a consequence, international human rights have 
a limited status of lex superior in the hierarchy of laws in Norway, similarly to Finland. 
Therefore, in the domain of human rights, the Norwegian system is not far from a 
monistic system.84 
The role of EU law in Norway is based on the implementation of the Agreement on the 
European Economic Area (EEA Agreement)85 and the Convention Establishing the 
European Free Trade Association (EFTA Convention)86 in Norwegian law. The EEA 
Agreement and EFTA Convention have been incorporated by act of Parliament. 
Therefore they are directly applicable as a part of Norwegian law. The status of EU law 
within the Norwegian legal system has been defined in the Act Implementing the EEA 
Agreement87. However, some bilateral treaties between Norway and the EU have been 
incorporated with use of a government regulation and their hierarchy in the 
Norwegian legal system is on the level of a regulation. EU law has a special role in the 
sources of law in Norway. The EEA Agreement establishes an obligation for courts and 
public officials to apply provisions of the EU treaties in line with EU law and the 
precedents of the CJEU. Therefore, the special doctrine of sources of law within EU law 
should also be applied when interpreting Norwegian legislation based on EU treaties.88 
The following chapters discuss health law and the fundamental and human rights 
which have particular relevance within the field. 
4.4. Health Law 
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4.4.1. Health Law within the Legal System 
In order to identify the human and social rights which, as suggested in the research 
paradigm, influence legislative decisions, it is necessary to determine in which area of 
law the topic of comparison belongs. By viewing the research topic within its position 
in the systemisation of laws it is also possible to examine the rights and principles 
which influence the legal institutions within that area of law.  
Pharmacy law can be examined from various perspectives and questions related to 
medicinal products can be placed within different areas of law. For example, the 
prevention of substance abuse by imposing sanctions is a question within criminal law 
and the protection of an inventor’s commercial interest against generic drugs is a 
question of patent law. Comparative law aims at viewing the legal system as a whole, 
and the scope of contingent problems from a functionalist perspective can span the 
entire legal system. Thus, comparison relating to pharmacy law covers matters which 
are usually dealt with within different areas of law. 
However, the principal knowledge interest in this work is related to the fundamental 
human rights which influence the legislator’s choices in regulating distribution of 
medicinal products and the pharmacy system as a whole. In this case, the central 
questions concern the relationship between individual citizens and other actors such 
as the state and commercial entities in pharmaceutical business. The foremost areas of 
law to be considered are social law and health law, while research on human rights 
within the national legal system is also related to constitutional law. Other areas of law 
which influence the structure and development of pharmacy systems include 
competition law, tax law, corporate law, consumer protection law and intellectual 
property rights. 
Within the systemisation of different areas of law, health law is considered to be either 
a field of public law parallel with social law or as such a part of social law.89 In any case 
it is beneficial to define both areas of law and to consider the general principles of 
both fields for the purposes of this research. 
Social considerations have permeated nearly all parts of welfare state legal systems. 
Despite of this, the manner of regulation and decision-making within social law is 
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distinctly different from the manner in which regulation and decision-making are 
carried out within core areas of the legal system such as criminal law and civil law. This 
makes the field of social law distinct from the core areas of the legal system. Social law 
can be defined as the set of legal norms which regulates social security and 
healthcare.90 
Within the traditional areas of law, social law has the closest ties with administrative 
law as the implementation of legal norms in the field is carried out mostly by 
municipalities, state authorities and institutions which are considered to be indirectly 
part of public administration. Furthermore, the same legal norms of administrative law 
are applied in most measures of legal protection in social law and in motions to appeal 
the decisions of municipal or state organs. Thus, the general principles of 
administrative law have particular relevance within social law and health law.91 
The matters which social law regulates, meaning social security and the healthcare 
system, call for special principles and legal institutions. Legal decision-making 
regarding matters of social law characteristically demands special expertise such as 
medical or psychological expertise instead of traditional legal expertise. Furthermore, 
decisions regarding individual rights are at the first instance often made by others than 
lawyers, for example by a doctor or a social worker. The quantity of matters at the first 
instance is significantly higher in matters of social security than in judicial decisions 
usually handled at first instance in court proceedings. Another characteristic of social 
law is that the legislation is in practice supplemented significantly by norms given by 
public authorities and officials such as interpretation guidelines provided by a state 
authority to its local offices. Decisions made within healthcare practice can have a 
significant role for an individual citizen and law can only provide a legal framework for 
practical situations requiring medical expertise. Thus, the ethical guidelines set by 
organisations of medical and other professionals provide supplementary social law 
norms.92 
In Finland the term corresponding to health law, terveysoikeus, has not been adopted 
into wider use. However, in Finnish legal literature the terms used to refer to the field 
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translate as medical law or law and medicine, lääkintäoikeus, and healthcare law, 
terveydenhuolto-oikeus. The former term deals particularly with legal questions 
concerning the relationship between a patient and a healthcare professional.93 The 
latter term is interchangeable with health law, and refers to legal matters regarding 
the healthcare system. The term health law, helserett, is generally used in the 
Norwegian legal research.  This Norwegian term for health law covers legal questions 
regarding the doctor-patient relationship as well as the healthcare system. 
The next chapter outlines the concept of health law used in this research and the 
central principles based on the understanding of health law within the Norwegian and 
Finnish legal systems. 
4.4.2. Concept of Health Law 
The following disciplines can be categorized under health law: biomedical or bio law, 
patient rights, reproductive law, medical law, healthcare law and medical ethics. As 
described above in the case of social law, health law has close ties to administrative 
law. Furthermore, the doctor-patient relationship and its liability matters have also 
been systemised through concepts of criminal law and the law of torts.94  
In Finland and Norway health law as an area of study has developed in conjunction 
with international human rights thinking. During the 20th century the way that the 
doctor-patient relationship is viewed has changed from a paternalistic approach to one 
which highlights the autonomy of the individual.95 National laws have been reformed 
in line with this change and due to the shortcomings regarding the way in which the 
legal system dealt with e.g. medical liability. The speed of scientific and technological 
development led to new demands for regulation within the medical science and 
healthcare. Finland and Norway have carried out law reform projects regarding health 
and healthcare services also as a part of ratifying international treaties. 96  
The human right to health is covered in Article 12 of the International Covenant on 
Economic, Social and Cultural Rights, which provides for “the right of everyone to the 
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enjoyment of the highest attainable standard of physical and mental health”97. Article 
13 of the European Social Charter imposes an obligation to the state to provide 
adequate assistance to “any person who is without adequate resources” and care in 
case of sickness98. Also, the Convention on Human Rights and Biomedicine99 sets 
requirements for the respect and protection of human dignity, self-determination, and 
privacy if individuals, equal access to healthcare and professional standards in the 
healthcare sector. International treaties do not specify standards for healthcare 
required from the state for every citizen regardless of the wealth of the state, nor do 
they impose sanctions on non-compliant states. However, they work towards putting 
pressure on ratifying states to establish national healthcare systems which are 
accessible to all citizens equally and to create a financial basis for their functioning 
within the means of the state.100 
The earliest regulations within health law concerned reproductive rights and medical 
ethics. During the 1970s Finland introduced reforms to modernise its legislation on 
abortion, medical sterilisation and the treatment of mental disease and disability. This 
first stage of reform worked towards eliminating defects in the freedom rights of 
patients. Simultaneously, the Finnish healthcare system underwent a significant 
overhaul and it was brought to fit the welfare state standards of the time. In the 
1980s, the Finnish Patient Injury Act (585/1986, FPIA) was introduced in order to 
improve the legal protection of patients against medical malpractice as well as to 
clarify the status of healthcare professionals and the manner in which liability was 
distributed. Under the FPIA, compensation was available to patients without the need 
to establish fault or negligence on behalf of medical personnel. The FPIA was also 
applied to cases of violations of the patient’s self-determination when alternative 
forms of treatment were available. Within the field of social welfare, Finland also 
introduced acts concerning social welfare, child welfare and welfare of substance 
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abusers as well as special legislation regarding resource allocation and the organization 
within the social welfare and healthcare system.101  
Similarly, development of patient rights and health law in Norway proceeded hand in 
hand with the emergence of human rights through international treaties in the post-
war period and the subsequent focus on individual rights. Other sectors of public 
administration were reformed in the spirit of the discussion on rule of law in the 1960s 
and 1970s. The 1980s saw increased discussion on patient rights. In the Medical 
Practitioners Act of 1980, the legislator in Norway introduced improvements to patient 
rights such as the right to information regarding one’s health and treatment, the right 
to access medical records and the right to participate during treatment. However, the 
Act did not provide for a statutory right to self-determination.102 
The shift of legal thinking in healthcare from the paternalistic approach to one focused 
on the rights of the individual led to a greater need for legislation regarding patients’ 
rights. Increasing discussion and research concerning health law by legal professionals 
in Finland and Norway contributed to this development.103 In both countries, 
regulation regarding patient rights was scattered across multiple legislative acts 
dealing with different aspects of health and the healthcare system as well as in 
criminal law and tort law. In order to establish a model of a doctor-patient relationship 
based on democratic professional cooperation and patient self-determination, the 
matter of patient rights needed to be brought together in one act.104 
As the first country in the world, Finland introduced a patient’s rights act in 1993. The 
Finnish Act on the Status and Rights of Patients (Laki potilaan asemasta ja oikeuksista 
785/1992) covers rights of the patient to good care and treatment, to information and 
to self-determination, the principle of informed consent as well as measures to protect 
the rights of the patient such as a notice right of the patient to the head of the 
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healthcare unit. Also, the institution of the patient ombudsman already in use in many 
healthcare units became compulsory under the new act.105 
The Norwegian Ministry of Health and Social Affairs commissioned a draft for a Bill on 
Patients’ Rights in 1988, which resulted in the government report NOU 1992:8 Lov om 
pasientrettigheter (Act on Patients’ Rights). The report was criticised due to the 
proposal to provide a right to treatment for cases of “a serious sickness, injury or 
handicap”. In their 1994 article, Kjønstad and Syse argued, that the distribution of 
healthcare services should not be allocated based on the seriousness of the medical 
condition as less ill patients can at times benefit from treatment even more than those 
who are very seriously ill. This criticism brings out the tension between the principle of 
need and the principle of equal access when brought into the context of factual 
circumstances: In order to ensure equal access, the state must also employ a standard 
for the allocation of resources within healthcare.  Kjønstad and Syse also pointed out 
that the requirement of serious sickness was open to interpretation which in practice 
would lead to unnecessary litigation. After several years of further discussion and 
preparation, the Norwegian Patients’ Rights Act (Lov 2. juli 1999 nr. 63 om pasient- og 
brukerrettigheter) came into force in 2001.106 
Along with this development, the doctor-patient relationship has become legal in 
nature. As the rights, responsibilities and liabilities within this relationship have 
become more clearly defined, the negative implications of regulation have also 
increased. The doctor-patient relationship is built on trust and confidence. A legalistic 
focus in this relationship can be problematic, as it becomes more open to conflict and 
the parties may need to focus on defending their rights and limiting their liability 
rather than on cooperation. This issue was also evident in the discussion regarding the 
Norwegian Patients’ Rights Act of 2001. Furthermore, poorly drafted and implemented 
regulation can limit the medical professional’s approach to providing care by bringing 
forth impersonal legal solutions rather than addressing the patient’s personal needs.107 
This was taken into account in the Finnish Patient Injury Act by structuring the process 
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of retaining recovery in a manner which highlights the right to compensation rather 
than placing blame.108 
The right to healthcare has been particularly challenging for the legislator both in 
Finland and in Norway. The legislator has paid attention to health law at a time when 
the “human rights train” was already passing by: The trend of codifying rights and 
entitlements to individual citizens preceded the health law discussion. Once the 
legislator started concrete work on matters relating health law, the tide had turned 
and it was no longer recommendable to grant new individual rights which the state 
and other public sector actors would then be obliged to fulfil. International 
conventions typically call for equal access to healthcare but they do not define 
standards for an individual’s right to healthcare. In Finland and in Norway, an 
individual only has the right for emergency treatment. In non-emergency cases, the 
fulfilment of the individual’s right to healthcare is contingent on prioritization and 
allocation of resources within the relevant healthcare unit and the overall healthcare 
system. The state’s participation in this process is largely financial, as policy decisions 
on prioritization are made in municipalities, counties and other local public sector 
actors. Decisions regarding prioritization in the day to day functioning of healthcare 
units are made by healthcare personnel such as doctors, nurses or head surgeons. In 
practice, through prioritization the healthcare professional evaluates which patient 
should be treated first and which kind of medical procedures are not only effective but 
also cost effective in a specific case109. Due to the scarcity of resources, it has been 
easier for the legislator to focus on providing legal remedies and control systems to 
protect patient rights instead of granting specific rights to the patient under law. Such 
legal claims to treatment could potentially become financially burdensome and 
unfeasible to fulfil.110 
In relation to health law, it is important to note that legal remedies and control 
systems have a very different practical relevance than for instance in private law or 
even in other areas of administrative law. Even in cases where the right to treatment is 
explicit and the law provides for remedial legal protection, restitution may of little 
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relevance or not possible in practice. For example, in case a patient in immediate need 
of medical assistance is denied treatment, the consequence for the patient can be as 
severe and as irreversible as death or permanent disability. This is why ethical 
considerations and professional ethical standards have a special role in health law. 
Medical ethics examines conflicting and congruent interests of the healthcare 
professional, patient and society in a critical manner and professional standards based 
on ethical considerations reduce the need for detailed regulation. For example, Article 
4 of the Convention on Human Rights and Biomedicine calls for the use of ethical 
standards in situations which are not covered by provisions of law.111 
However, relevant rights within health law cannot be left to rely only on ethical 
standards. Within a welfare state, social human rights and the principles of health law 
should be evident also in written law112. This is the case in the Finnish Constitution as 
well as the Norwegian Constitution where many of the rights relevant to health law 
have the status of fundamental rights. The underlying constitutional values relevant to 
health law include respect for human dignity, the rights and freedoms of the individual 
and justice. In addition to the fundamental rights described in the following chapter, 
these underlying principles have a role in interpreting legislation regarding health.113 
Legislation regarding pharmaceutical care is part of health law and the principles of 
health law apply in the field. As I have described in the Introduction to this research, 
the distribution of medicinal products includes a transaction from the health 
professional to the patient. Pharmacies function as private businesses and the 
recipients of their service and products are not only patients but customers. Thus, the 
pharmacy sector can be regulated more directly and in a more interventional manner. 
Since the transaction is tangible, also its value can be determined more easily. 
Furthermore, the actors are separate from each other. In healthcare, the expenses and 
income of the healthcare are public sector expenses and income. However, in the 
pharmacy sector the expenses and income are allocated to the proprietor of the 
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pharmacy and state expenses consist of reimbursement of medicine expenses for 
citizens. Also, the citizen carries the costs of their pharmacy purchases to a greater 
extent than in healthcare: as a rule, the pharmacy establishment runs on its revenue 
from sales whereas a healthcare unit is funded mostly by the public sector. 
All of the abovementioned factors lead to a greater ability of the state to monitor its 
expenses relating to pharmaceuticals. The state also has a greater selection of 
mechanisms with which it can impact the sale and prices of medicinal products. The 
state can for example impose tax-like payments on pharmacies whereas the same 
would not increase the states revenue if imposed on hospitals run on public funds. 
Despite the differences between the pharmacy sector and healthcare, the same 
principles of health law apply to the sale of medicinal products and to the profession of 
the pharmacist. Pharmaceuticals have an essential role in healthcare and in preventive 
care. Thus, the state must take the principles of health law into consideration in its 
legislation concerning medicinal products and the pharmacy sector. The next chapter 
outlines the central principles and fundamental rights which impact the legislator’s 
decision-making in the field and which have been used in determining the specific 
focus of this research. 
4.4.3. Social Human Rights as Fundamental Rights 
Health law deals with the following rights: human dignity, the patient’s right to self-
determination, right to privacy, right to health, access to healthcare and equal 
treatment. These rights represent the social rights family of human rights. It is 
characteristic of social rights that their fulfilment is carried out collectively and 
gradually. The state is obliged to commit to fulfilling and promoting these rights 
according to its level of development and available resources.114 
The following rights relevant to health law are fundamental rights in the Finnish and 
Norwegian legal systems. Equality of individuals under the law has been ensured in 
CoF Section 6 and in CoN Article 98. The fundamental right for equal treatment is 
central for ensuring justice in the health sector. The right to privacy has been ensured 
in CoF Section 10 and CoN Article 102. Both the Finnish and the Norwegian 
constitution ensure the right to life, personal liberty and integrity (CoF 7.1 §, CoN 93 §, 
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94.1 §, 102.2 §). These rights form the foundation of the principle of self-
determination. Social human rights ensured in CoF Section 19 ensure the “right to 
receive indispensable subsistence and care” for those without sufficient means and a 
requirement for the state to guarantee “adequate social, health and medical services 
and promote the health of the population”. The Norwegian Constitution does not 
include a corresponding provision. However, CoN Article 104 includes an obligation for 
the state to ensure “necessary economic, social and health security” for children. 
Together with the right to life, rights relating to social assistance and healthcare ensure 
the minimum requirements for the fulfilment of human dignity.115 
Since social human rights are strongly connected to resources, equal treatment has a 
central role in the fulfilment of all social rights. Equal treatment can be promoted in 
different ways. Under the first example, labour market old age pension, the social 
benefit rises with an individual’s labour earnings. Another option is to treat everyone 
similarly irrespective of their situation which has been the case with child benefit in 
Finland. The third option is to distribute benefits based on need.116 
In Finland and Norway, the most significant manner in which the state promotes equal 
treatment in relation to medicinal products is reimbursement of medicine expenses 
under national social insurance schemes. In both countries the system employs the 
two latter forms of equal treatment. Firstly, the rates at which costs are reimbursed 
are the same for everyone. However, medicinal products are included within the scope 
of reimbursement according to the medical purpose and need which they serve. 
Furthermore, individual exceptions can be made when necessary and social assistance 
for medicine expenses is available for those who otherwise could not afford their 
necessary medicinal products.  
In relation to social rights the state’s obligations can work on several levels. On the first 
level, the state must respect a relevant right or freedom. This is more applicable to civil 
and political rights – however, human dignity requires respect on behalf of the state. 
No-one should be subjected to inhumane treatment. An example under health law 
would be the abolishment of forced castration of the mentally disabled in Finland in 
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1970117. The next level of the state’s fulfilment of social rights is protection. For 
example, the right to health requires that the state has sufficient institutions of 
pharmacovigilance in place to protect its citizens from deficient medicinal products. 
This is done through the requirement of a market authorization for all medicinal 
products which is followed up with meticulous reporting and supervision processes for 
the products which have been placed on the market. Thirdly, the state has an 
obligation to ensure the fulfilment of social rights such as minimum income and 
emergency healthcare. Lastly, depending on the nature of the obligation defined in the 
relevant international convention or national act of law, the state may be obliged to 
promote the relevant social right. Promotion makes the nature of the obligation 
progressive and it sets a requirement for the state to strive for and to achieve progress 
in the relevant field. One example of this is promotion of public health through 
allowing the sale of nicotine replacement products in retail stores and kiosks in Finland 
for the purpose of lowering the threshold to quit smoking.118  
4.4.4. Functionalist Comparison of Pharmacy Legislation 
Regulation concerning the pharmacy sector and medicinal products needs to take into 
account of fundamental rights ensured in the constitution as well as the underlying 
principles of health law. However, the central question which the state has to answer 
when regulating the pharmacy sector and medicinal products is: “How can the state 
ensure equal access to pharmaceutical care for all citizens?” 
This question can be divided into three different and at times conflicting aims. Firstly, 
the state must ensure that all citizens have reasonable access to pharmaceuticals in 
that they are available without unreasonable delay or effort. Thus, the state will for 
instance need to ensure that the pharmacy network is comprehensive enough that 
individual citizens do not need to travel long distances or wait a long time for their 
medicine. Secondly, the state must ensure that all citizens have sufficient means to 
afford to pay for their necessary medicines. Thirdly, the state must ensure that the 
pharmaceutical care which the citizens receive is effective, appropriate and safe. The 
focus of this research is on these questions. 
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The legal institutions with which the state regulates these three questions of access, 
price and effective care are interlinked and impacted by each other and the remaining 
rights relating to health. With this in mind, I have chosen the following institutions as 
the main topics of comparison: (1) pharmacy ownership and management; and (2) 
price control mechanisms and reimbursement of medicine expenses. This research 
describes and to some extent explains the legislative framework and institutions as 
well as their origins, development and function for Finland in chapter 6 and for Norway 
in chapter 7. Even though these functionally equivalent institutions have been chosen 
based on certain central rights and principles relevant to the pharmacy sector, during 
the comparison of the institutions other factors relating to the pharmacy sector have 
also been highlighted from time to time.  
Before examining the two main topics of comparison, I have described a number of 
matters which are central for building an overall understanding of the retail sale of 
pharmaceutical products. These topics are common to Finland and Norway and many 
of them are regulated by international treaties or on EU-level. These topics are central 
from the perspective of safety and effectiveness. However, they are less political in 
nature as the specific norms under the topics are defined more by technical and 
scientific requirements than by questions of resource allocation. 
5. Introduction to Pharmacy Legislation 
This research will deal with pharmacy legislation in Finland and Norway in the 
following manner. First, this chapter 5 will introduce the international and European 
regulatory framework which is applicable in both countries. This chapter will also 
describe features of pharmacy legislation which are common to the distribution of 
medicinal products in Finland and Norway. In order to provide a holistic view of the 
level of detail with which medicinal products and the behaviour of actors on each level 
of the distribution chain are regulated, this chapter discusses topics such as 
pharmacovigilance, professional standards and hospital pharmacies. The knowledge 
interest of this research is in the choices made by the legislator regarding the sale of 
medicinal products to the public. Thus, this research will not discuss these individual 
topics in detail. 
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Chapters 6 and 7 will provide an overview of the pharmacy systems of Finland and 
Norway respectively. These chapters will focus on relevant permits required for 
pharmacy businesses and price control mechanisms for medicinal products as well as 
regulatory matters with a unique impact on the pharmacy market in each country. 
5.1. Ethical Standards 
The International Pharmaceutical Federation (Fédération internationale 
pharmaceutique, FIP) has adopted the “Statement of Professional Standards – Code of 
Ethics for Pharmacists” regarding the main principles which should be included in the 
codes of ethics of national pharmaceutical organizations119. The statement places 
pharmacists first and foremost into the context of the overall health system. It 
emphasizes their role as “expert[s] on medicines” and the aim of helping patients 
maintain and achieve good health, whether remunerated or not. The statement also 
takes into account the significance of pharmacists in other roles than in a clinical 
relationship with patients, for example in developing new medicinal products, 
education and policy development. The principles cover topics such as integrity and 
honesty, professional autonomy, the patient’s best interest, confidentiality of patient 
information, regulatory compliance, respect for cultural diversity and professional 
development. 
The Association of Finnish Pharmacies has adopted a “Code of Ethics for Pharmacy 
Activity” and established a “Board of Professional Ethics” which issues statements and 
guidelines on questions of professional ethics in the pharmacy sector120. The 
Norwegian Pharmacy Association (Apotekforeningen, former Apotekerforeningen), the 
Norwegian Association of Pharmacists (Norges Farmaceutiske Forening, NFF) and the 
Norwegian Association of Pharmacy Technicians (Farmasiforbundet) adopted “Branch 
Standards for Pharmacies” in 2003.121 
5.2. International Treaties 
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Medicinal products and the pharmacy sector are impacted by provisions of numerous 
international treaties. Pharmaceutical patents are subject to the TRIPS Agreement122 
which provides for a 20-year patent protection period for new medicinal products. 
Patent protection aims at incentivizing research and innovation by providing 
protection from competition and thus enabling the patent holder to charge higher 
prices during the protection period. 123 
Many of the international treaties concerning medicinal products regulate narcotics 
and psychotropic substances124. The Council of Europe is also working on the recent 
MEDICRIME Convention125 which covers counterfeit drugs. 
The impact of these treaties is that national legislation concerning medicinal products 
and their distribution must ensure protection of relevant patents and trademarks as 
well as refrain from establishing barriers to trade under the relevant treaties. Thus, 
national health policy and the national pharmacy system need to be formulated in 
accordance with these treaties. 
International human rights and social rights treaties in the Finnish and Norwegian legal 
systems, as well as their impact on pharmacy legislation, are discussed in chapter 4.3. 
5.3. European Union Legislation 
EU legislation differentiates between medicinal products for human use and for 
veterinary use. For the purposes of this research it is sufficient to outline the legislative 
framework only regarding medicinal products for human use. Medicinal products are 
regulated by the EU Directive 2001/83/EC on the Community code relating to 
medicinal products for human use (“Directive on medicinal products” for the purposes 
of this research) and by the EU Regulation 726/2004 laying down Community 
procedures for the authorisation and supervision of medicinal products for human and 
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veterinary use and establishing a European Medicines Agency (“Regulation on 
centralized procedure” in this research). The provisions under the Directive have been 
implemented in national law in Finland and Norway (FMA 21–21c §, FMR 9–10f § and 
NMA 8 §, NMR chapters 2–6). 
The European Union has enacted legislation concerning the manufacture, wholesale, 
entry into the retail market and classification of medicinal products, and 
pharmacovigilance. EU legislation has left pricing and the inclusion of medicinal 
products in national health insurance systems subject to the Member States' national 
legislation (Art. 4.3, Directive 2001/83/EC). 
In the following chapter I will briefly summarize the EU framework regarding medicinal 
products and the scope of legislative choice left for Member States regarding 
distribution of medicinal products. 
5.3.1. Definition of Medicinal Product 
The Directive on medicinal products for human use defines a medicinal product as: 
“Any substance or combination of substances presented for treating or 
preventing disease in human beings. 
Any substance or combination of substances which may be administered 
to human beings with a view to making a medical diagnosis or to 
restoring, correcting or modifying physiological functions in human 
beings is likewise considered a medicinal product.”126 
Finland and Norway both define medicinal products in a similar manner in Section 2 of 
the Norwegian Medicines Act (Lov om legemidler m.v.: legemiddelloven, 4. desember 
1992 nr. 132, NMA) and section 3 of the Finnish Medicines Act (Lääkelaki 
10.4.1987/395, FMA). The directive is applied to medicinal products produced 
industrially on the internal market127. Special provisions regarding immunological 
medicinal products, radiopharmaceuticals and medicinal products derived from human 
blood or human plasma in the Directive are excluded from the following review. 
                                                     
126
 Directive 2001/83/EC on the Community code relating to medicinal products for human use, Article 
1, subsection 2.  
127
 The directive excludes e.g. medicinal products manufactured in pharmacies. 
51 
 
5.3.2. Marketing Authorization 
Any medicinal product intended to be distributed to consumers in the internal market 
must have a market authorization. The Directive on medicinal products sets forth an 
authorization procedure for placing a medicinal product on the market in a Member 
State. The Directive defines the procedure and requirements, including 
documentation, clinical data and deadlines, for marketing authorization requests. 
Applicants must be established in the European Community. 
There are three distinct cases and procedures for obtaining a marketing authorization. 
The first case applies for medicinal products not yet placed on the market in any 
Member State and which do not have a marketing authorization in place or pending in 
any Member State. In such cases, the request is submitted to the competent authority 
of the relevant Member State. For Finland, the competent authority is the Finnish 
Medicines Agency, Fimea (Lääkealan turvallisuus- ja kehittämiskeskus). The Norwegian 
competent authority is called the Norwegian Medicines Agency (Statens 
legemiddelverk). Under the Directive, the competent authority has the right to grant a 
marketing authorization for the market within the Member State. 
In the second case, the applicant already has a market authorization for the medicinal 
product in one of the Member States (reference state). In such cases, a mutual 
recognition procedure is applied. Under this process, the applicant informs the 
reference state authority of its intention to apply for additional marketing 
authorizations and receives an assessment report from the authority. The applicant 
then submits its application along with the documentation received from the reference 
state to the competent authority of each relevant Member State. The Member States 
will then grant marketing authorizations for their respective markets. However, it is 
possible that a Member State has reason to suppose that the product may pose a 
threat to public health or that Member States issue diverging decisions on the matter. 
In such cases, if they cannot agree upon a joint decision, the entire matter or any 
remaining questions will be submitted for community level review. 
The Regulation on centralized procedure for medicinal products sets forth a 
centralized procedure for obtaining market authorization for certain medicinal 
products listed by the Commission. Under the centralized procedure, the applicant 
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applies for market authorization from the Commission for the entire internal market. If 
the authorization is granted, the medicinal product can be distributed subject to the 
same conditions in all Member States. 
Final decisions regarding marketing authorizations under the mutual recognition 
procedure and the centralized procedure are made by the Standing Committee on 
Medicinal Products for Human Use (the Standing Committee) working under the 
European Commission. The European Medicines Agency (EMA) is the community level 
supervising body for medicinal products. The Committee for Medicinal Products for 
Human Use (the Committee) is responsible for reviewing marketing authorization 
requests and for drafting opinions of them on behalf of the Agency for the Standing 
Committee. 
5.3.3. Exceptions to Marketing Authorization Requirements 
Article 10 of the Directive on medicinal products provides for a simplified procedure 
for generic drugs. A generic drug is a medicinal product which has the same 
pharmaceutical form and is bioequivalent with, and which has the same qualitative 
and quantitative composition in terms of active principles as a medicinal product 
authorized in a Member State or within the Community128. Generic drugs are subject 
to a lighter review process. If the applicant can demonstrate that its product meets the 
requirements of Article 10, the applicant does not need to provide toxicological or 
pharmacological test results or results of clinical trials for the market authorization 
process. 
Additionally, homeopathic and traditional herbal medicinal products are exempt from 
the marketing authorization process and are instead subject to a simplified registration 
process (Art. 13 and 16a, Directive 2001/83/EC)129. For a product to qualify as a 
traditional herbal medicinal product, the applicant must prove that it has been in use 
for 30 years or more, including 15 years within the Community. The competent EU 
authority responsible for the registration process and supervision is the Committee for 
Herbal Medicinal Products under the EMA. 
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5.3.4. Special permission for compassionate use 
Article 83 of Regulation 726/2004 allows Member States to make an exception to the 
marketing authorization procedure for the purposes of compassionate use. This means 
that Member States can provide a special exception for introducing unauthorized 
medicinal products to the market for a specific person or a specific group of patients 
on humane grounds. The aim of the exception is to facilitate the use of new or 
extraordinary medicinal treatments for patients with a life threatening, chronic or 
seriously debilitating disease. The Regulation requires that the patient cannot be 
treated with an authorized medicinal product and that the exempted product is either 
the subject of a marketing authorization application or undergoing clinical trials. The 
exemption under Article 83 also covers situations where there are plans to use an 
authorized medicinal product for a target group or a therapeutic purpose other than 
the permitted use under the marketing authorization130. 
5.3.5. Manufacture, Import and Wholesale 
The Directive on medicinal products for human use requires that Member States 
require authorization for manufacture and import of medicinal products. The Directive 
defines minimum requirements for the standards to be applied to such authorizations. 
According to article 77 of the Directive, wholesale of medicinal products is also subject 
to authorization. However, in case the entity engaging in wholesale is in possession of 
an import or manufacturing authorization, such authorization also covers wholesale. 
5.3.6. Classification of Medicinal Products 
Title VI of Directive 2001/83/EC classifies medicinal products under two categories: 
medicinal products subject to medical prescription and medicinal products not subject 
to medical prescription. The Directive allows Member States to define three 
subcategories of medicinal products subject to prescription. In defining subcategories, 
the Member State shall take into account, for example, the risk of adverse effects, 
misuse and abuse of the medicinal product. (Art.70, Directive 2001/83/EC) 
In Norway prescription drugs have been classified into groups A, B and C based on the 
level of their addictive effects (NMR 7:3 §). Group A includes highly addictive medicinal 
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products, whereas prescription drugs in group C do not include any risk of addiction. 
The Norwegian Medicines Agency maintains a list of medicinal products subject to 
prescription in Norway. Prescription drugs have not been categorized in any such 
manner under the FMA. However, both in Finland and in Norway prescription drugs 
have been classified for purposes of their respective national health insurance 
systems131. Both countries also utilize the international Anatomical Therapeutic 
Chemical Classification System (ATC) in deciding maximum wholesale prices for 
medicinal products and in defining the therapeutic purpose of use for prescription 
drugs reimbursed under national health insurance. 
Medicinal products which, according to their marketing authorization, are not subject 
to prescription are called over-the-counter drugs. Marketing authorizations for 
products with a different dosage or package size of the same medicinal substance can 
have different conclusions regarding prescription even if they are covered by the same 
marketing authorization. For example, smaller packages with a low dosage of certain 
anti-inflammatory painkillers which are usually subject to prescription may be sold 
over the counter. Fimea maintains a list of dosages and package sizes for medicinal 
products which can be sold over the counter132. The Norwegian Medicines Agency can 
exclude certain dosages and package sizes according to Section 7.6 the Norwegian 
Medicines Regulation. On the other hand, for some medicinal substances all dosages 
and package sizes are authorized as non-prescription drugs. Homeopathic and 
traditional herbal medicinal products which are subject to registration are also sold 
over the counter. 
Pharmacies also sell a variety of other products, such as cosmetics, nutritional 
products and other products which are not medicinal products subject to marketing 
authorization or registration. They may however be covered by regulation concerning 
medical devices, biocides, CE-marking, food safety and consumer protection and 
subject to supervision by relevant authorities. EU and national legislation concerning 
medicinal products does not apply to these other products and they may be freely sold 
in retail stores. However, they constitute a significant source of revenue for 
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pharmacies and may serve as ancillary means of advancing health. This research will 
refer to such products jointly as non-medicinal products. 
5.3.7. Prescription Drugs Subject to Additional Restrictions 
Article 71 of Directive 2001/83/EC defines the criteria by which medicinal products 
should be classified further. According to the Directive, drugs can be subject to 
prescription, special prescription or restricted prescription. Member States can apply 
restricted prescription to a medicinal product which is reserved only for treatment in a 
hospital environment or which should be diagnosed in a hospital or special diagnostic 
institution or which can cause very serious adverse reactions and thus requires 
prescription by a specialist and special supervision throughout the treatment. 
Special prescription can be applied to a medicinal product classified as a narcotic or 
psychotropic product or which includes the risk of substance abuse or addiction 
(Directive 2001/83/EC: Art. 71.2). Narcotics are subject to several international treaties 
and their use, distribution, handling and storage are heavily regulated. International 
treaties on narcotics and psychotropic substances have also been adopted in EU 
legislation133. Medicinal products can also be subject to doping regulation. The Finnish 
Criminal Code (Rikoslaki, 39/1889, FCC) and the Norwegian Criminal Code (Almindelig 
borgerlig Straffelov, straffeloven – strl. 22. mai 1902 nr. 10, NCC) both include 
provisions on narcotics and doping substances. (FCC 44:5a – 8 §, chapter 50; NCC 162 
§, 162b §) 
The Finnish Narcotics Act (Huumausainelaki, 373/2008) provides for an authorization 
process for manufacturing, import, export and handling of narcotics. The Act also 
defines additional requirements for data collection, maintaining records, notification 
duty, storage, transportation, disposal, supervision, sanctions and various other 
aspects of handling narcotics. The Finnish Government Decree on substances, products 
and plans which are classified as narcotics 543/2008 provides a list of substances and 
products which are subject to the Finnish Narcotics Act. The Government decree 
705/2002 lists medicinal products which are classified as doping products in Finland.  
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Chapters 8 and 8a of the Norwegian Medicines Act govern narcotic drugs and 
substances which can be used for manufacturing narcotics. The Norwegian Narcotics 
Regulation (Narkotikaforskriften, 14. februar 2013 nr. 199) provides for detailed 
practices and control mechanisms which must be applied in the manufacture, 
transportation, storage, industrial use, import, export and sale of narcotics. The 
Regulation includes a list of substances which have been classified as narcotics. 
Medicinal products classified as doping substances have been listed in the Regulation 
on Doping Substances (Forskrift om hva som er dopingmidler, 30. april 1993 nr. 318).  
5.3.8. Pharmacovigilance 
Directive 2001/83/EC title 9 and Regulation 726/2004 chapter 3 lay out detailed 
requirements for pharmacovigilance in Member States. Pharmacovigilance refers to 
the activities and processes for quality control and safety of medicinal products. EU 
legislation includes strict pharmacovigilance obligations on marketing authority 
applicants and holders as well as on manufacturers, importers and wholesale 
companies. From the perspective of pharmacies, pharmacovigilance sets standards for 
the way medicinal products are distributed, handled, manufactured and stored inside 
the pharmacy. However, pharmacies also have an obligation to monitor the quality of 
the products which are delivered to them and to report on matters of drug safety to 
the national medicines agency. In practice reporting covers data on reclamations from 
the pharmacy or the customer and on any adverse effects that the pharmacy becomes 
aware of. Under the EU framework the Pharmacovigilance Risk Assessment Committee 
working under the EMA is responsible for assessing and monitoring drug safety 
(Directive 2001/83/EC Art. 27.1). 
5.4. Professional Standards and Regulation 
Sections 6 and 7 describe the main features of pharmacy systems in Finland and 
Norway respectively. In addition to the main features outlining the system, ethical 
standards, international conventions and EU legislation, the domestic law in both 
countries includes detailed regulation on medicinal products. In order to fully 
understand the pharmacy sector, it is important to be aware of the professional and 
regulatory requirements which impact the everyday business in the retail sale of 
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pharmaceuticals. This section summarizes certain domains of regulation which 
otherwise are excluded from the scope of law comparison. 
5.4.1. Professional Standards and Special Regulation 
There are special requirements for the professional qualifications of pharmacy 
personnel in Finland and Norway. These requirements are set in the Finnish Act on 
Health Care Professionals (Laki terveydenhuollon ammattihenkilöistä 559/1994) and 
the Norwegian Act relating to health personnel etc. (Lov om helsepersonell m.v.: 
helsepersonelloven – hlspl. 2. juli 1999 nr. 64). These acts for example define the level 
of education required for the use of the professional title pharmacists and set special 
obligations relating to confidentiality. Furthermore, both the Finnish Medicines Act 
and the Norwegian Pharmacy Act include a requirement of sufficient personnel in 
order to fulfil the pharmacy’s service obligation and to ensure drug safety (FMA 56.1 §, 
NPA 4:3 §). 
Pharmacies in Norway have an obligation to sell any medicinal product introduced into 
the domestic market if this is necessary for the pharmaceutical care of the patient 
(NPA 6:2§). In Finland, the capacity of pharmacies to provide necessary products has 
been ensured through a requirement for a sufficient stock and offering in the 
pharmacy (FMA 55.1 §). Pharmacies also have an obligation to provide information 
and guidance to patients on medicinal products and their prices and if necessary 
instruct the patient to consult a doctor (FMA 57 §, NPA 2:8 §). Regulation also sets 
standards for the facilities of the pharmacy both for purposes of general drug safety, in 
house manufacturing and customer service (FMA 56.2 §, FMD 15 §, NPA 5:5 §, NPR 21 
§). Pharmacy opening hours must be sufficient to ensure sufficient service in the area 
and opening hours can be restricted on Sundays (FMA 55 §, NPR 25 §, NPA 5:2 §). 
Marketing and advertisement of medicinal products to healthcare professionals and to 
the public is carefully regulated (FMA 91–94 §, NMA chapter 7). Activities such as 
online sale, dose-dispensing of medicinal products to individual patients and electronic 
prescription are also covered in relevant legislation, supplemented by government 
decrees and regulations. 
Privacy and data protection are critical questions in the health sector. Pharmacies have 
a strict confidentiality obligation and their processes and facilities need to ensure the 
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protection of personal and sensitive information. This also includes the perspective of 
data security. Pharmacies need to have protocols in place not only for processes in 
their everyday business but also in exceptional circumstances. Pharmacies’ data 
systems often also constitute personal data registers. Data protection and personal 
information are covered in the Finnish Personal Data Act (Henkilötietolaki 523/1999) 
and the Norwegian Personal Data Act (Lov om behandling av personopplysninger 
(personopplysningsloven) 14. april 2000 nr. 31). 
Hospital pharmacies work in connection with hospitals and their purpose is to ensure 
the pharmaceutical care and distribution of medicinal products inside the relevant 
hospital. Hospital pharmacies are usually publicly owned and they may distribute 
medicinal products to other public healthcare units. Hospital pharmacies play a role in 
the professional field in pharmacy as well as in the pharmaceutical market. However, 
the manner in which their role in the market has been resolved in relation to other 
public sector actors and to privately owned pharmacies is not central for the 
knowledge interest of this research. (FMA 61–66a §, NPA 1:3 § subsection c, 2:5§) 
It is not necessary for the purposes of this research to outline the processes for 
supervision, sanctions and administrative processes for appealing decisions of 
supervising bodies in the pharmacy sector. The Finnish Medicine Agency (Fimea) and 
the Norwegian Medicines Agency are the supervising bodies regarding medicinal 
products and pharmacies. The appellate body for decisions of the Norwegian 
Medicines Agency in questions relating to pharmacy licenses is the Appeal Board for 
Pharmacies (Apotekklagenemnda) under the Norwegian Appeal Board for Health 
Personnel (Statens helsepersonellnemnd). In Finland, the Fimea’s decisions regarding 
pharmacy licenses can be appealed in the relevant administrative court. 
6. Legislative Framework of Pharmaceutical Distribution in Finland 
6.1. Finnish Medicines Act 
The principle legislative act governing medicinal products and their distribution is the 
Finnish Medicines Act. The Act implements EU-legislation regarding manufacturing, 
import and wholesale of medicinal products as well as pharmacovigilance and 
marketing authorizations. Chapter 6 of the Act concerns pharmacies and retail of 
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medicinal products. The FMA also covers pharmaceutical care in hospitals, health 
centres and in social care centres as well as direction and supervision of 
pharmaceutical care. 
The Finnish Medicines Decree (Lääkeasetus 24.7.1987/693, FMD) has been issued 
based on the FMA and it provides more detailed provisions regarding the topics 
covered by the FMA. 
6.2. Development of Pharmacy Legislation in Finland 
6.2.1. Background and History 
The first pharmacies in Finland were founded in Turku and in Vyborg in 1689 under a 
royal privilege. Pharmacy privileges were personal save for the privilege issued to the 
Royal Academy of Turku in 1755 which ultimately developed into the Helsinki 
University pharmacy. Pharmacy privileges were personal, assignable and subject to 
inheritance. During the 1800s several committees discussed the development of the 
pharmacy system and considered numerous alternatives from complete freedom of 
establishment to a state-owned pharmacy network. 134 
The Finnish Act on Pharmacies (apteekkilaitoksesta annettu laki 4/1928) and the 
Finnish Pharmacy Goods Act (apteekkitavaralaki 374/1935 were enacted during the 
early years of Finnish independence. Under the Act on Pharmacies, the system 
functioned on the basis of the principle of personal ownership subject to a pharmacy 
license. These two acts governed the pharmacy sector until late 1980s and were 
amended several times during their existence. The development of the Finnish 
pharmacy system was influenced by changes in society, world events and advances in 
medical science and the pharmaceutical industry. For example, prohibition in 1920s 
increased turnover while the depression in 1930s was a difficult time for pharmacies. 
The Second World War called for a complete reorganization of distribution chains. 
After the war, the pharmacy system and legislation was adapted to suit the rapid 
development of new pharmaceutical innovations and industrial manufacturing of 
medicinal products.135 
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6.2.2. Development of the Finnish Medicines Act 
The Finnish Medicines Act was adopted in 1987. The FMA replaced the two main 
legislative acts regulating medicinal products and the pharmacy sector, the Finnish Act 
on Pharmacies and the Finnish Pharmacy Goods Act. Both acts were out of date and 
patched with numerous small amendments over several decades. The chief aims for 
enacting the new Finnish Medicines Act was to bring together regulation concerning 
medicinal products and pharmacies under one legislative act, to modernize the 
terminology used in the legislation and to clarify certain ambiguities and structures in 
the existing legislation. The new Act did not change the main features and structures 
of the Finnish pharmacy system.136 
The Act has been modified and revised several times. The first major amendments to 
the FMA were made in 1993 in connection with Finland joining the European Economic 
Area and with Finland’s EU membership in 1995. The next significant amendments 
were adopted in the 1990s when the pharmacy market faced increasing criticism due 
to the high level of regulation regarding pharmacy ownership and lack of competition 
among pharmacies. Certain features of the pharmacy permit system were simplified 
and made more flexible. However, unlike in Norway the main structure of the Finnish 
pharmacy system has not been changed in the past decades.  
After the enactment of the new Finnish Medicines Act, discussion regarding the 
pharmacy sector has become more focused on the prices of medicinal products and 
competition within the sector. The legislator has been concerned about the limitations 
for competition in the field due to the pharmacy license system on one hand and due 
to asymmetric information between the consumer, healthcare professionals and the 
pharmacy. It is clear that the market for medicinal products does not function in 
normal way: It is often the doctor and not the patient who chooses the medicinal 
product on behalf of the patient137.  
The most significant changes that have been implemented in the Finnish pharmacy 
system after the enactment of the FMA have been in the field of price regulation. In 
2002 generic substitution was introduced in Finland and in 2008 internal reference 
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pricing was adopted in order to reduce public subvention costs for medicinal products. 
In 2005 retail sale of nicotine replacement products was permitted outside of 
pharmacies.138 In adopting these methods, Finland has followed the general trend of 
Northern European countries. 
6.3. Main Features of the Finnish Pharmacy System 
6.3.1. Retail Sale of Medicinal Products 
The sale of medicinal products to the public is only allowed for pharmacy 
establishments. Pharmacy establishments are defined as pharmacies, subsidiary 
pharmacies, pharmacy service points and pharmacies engaging in online sale (FMA 38 
§). The sale of homeopathic and traditional herbal medicinal products is permitted also 
outside of pharmacies, unless otherwise stated in the relevant registration (FMA 38a 
§). The sale of nicotine replacement products is permitted outside of pharmacies, e.g. 
in retail stores and kiosks (FMA 54a §).139 
6.3.2. Pharmacy Ownership and Management 
In Finland the exercise of pharmacy activities is subject to a pharmacy license, which 
covers pharmacy ownership and management. Fimea is the competent authority 
responsible for issuing pharmacy licenses. The number of pharmacies in Finland is 
limited by the pharmacy license system: on its own proposal, Fimea decides on the 
establishment of new pharmacies and other pharmacy establishments, number of 
pharmacy establishments and their geographical distribution on the basis of local 
demand and the requirement of equal access to healthcare. In cases reduced local 
demand Fimea can decide on the discontinuation of the license for a pharmacy 
establishment, if demand is sufficiently met by other pharmacy establishments in the 
area. Municipalities can propose the establishment of a new pharmacy establishment 
or amendments to the location of existing pharmacy establishments in their area. 
(FMA 40 § and 41 §) 
In addition to the establishment of a new pharmacy, licenses become open for 
application when a pharmacy owner is granted with a new license for another 
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pharmacy, retires or decides to discontinue their pharmacy business, or when a 
pharmacy owner loses their pharmacy license or otherwise becomes ineligible for 
holding a pharmacy license. Section 43 of the FMA defines the criteria of eligibility for 
license holders and the factors which Fimea shall take into account when choosing the 
best out of several candidates. Firstly, a pharmacy license can only be granted to a 
citizen of an EEA state who is a certified Master of Pharmacy. The law also requires 
that the license holder has full legal competence and has not been declared bankrupt. 
Among several candidates, the pharmacy license shall be granted to the person who 
can be considered to have the best overall capability to run a pharmacy establishment.  
The factors to be taken into consideration in assessing overall capability include the 
applicant’s previous work at a pharmacy or in other pharmaceutical services, previous 
pharmacy ownership, relevant studies, management skills and other activities. Thus, a 
doctoral degree in pharmacy, a certified course in business administration and for 
example a significant position of trust in a professional organization such as the Finnish 
Pharmacists' Association can work as an advantage in the application process. (FMA 
43.3 §)140 
The pharmacy license is personal and non-transferable (FMA 44.1 §). The license 
holder must manage the pharmacy personally, although the law provides for special 
conditions such as illness (FMA 44.2 ). Each pharmacy owner runs their business as a 
sole proprietor and their business is taxed accordingly141. Thus, pharmacy chains in 
which each pharmacy is under common control of one pharmacy group are not 
permitted in Finland. 
A pharmacy license holder can only own and run one pharmacy at a time. Pharmacy 
owners can however apply for any pharmacy license which has become available. If a 
pharmacy owner is issued with another pharmacy license, the former license expires 
and it is opened for application (FMA 44.1 §). The Finnish Medicines Act provides for a 
transitional period during which one person can own and run two pharmacies when a 
pharmacy owner has been issued with a new pharmacy license and the old pharmacy 
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has not yet been sold (FMA 46 §). Pharmacy owners have the right to own and run 
their business until the age of 68 (FMA 45 §), which is the latest age of retirement in 
Finland.  
Section 50 of the FMA defines the cases in which Fimea will revoke a pharmacy license. 
These include bankruptcy, legal incompetence, loss of certification as Master of 
Pharmacy, inability to run a pharmacy due to illness or substance abuse, criminal 
conviction of two years in prison or more, significant abuse of the pharmacy license, 
failure to react to a written warning under FMA Section 51 or other obvious 
incompatibility for exercising pharmacy business. Fimea can issue an oral or written 
warning under Section 51 of the FMA in cases where the license holder has infringed 
the provisions of the FMA or another regulation issued under the FMA, has acted 
erroneously, negligently or inappropriately but which do not warrant prosecution in 
court. 
6.3.3. Subsidiary Pharmacies and Pharmacy Service Points 
A pharmacy owner can be issued with a license to up to three subsidiary pharmacies 
(FMA 52.1 §). Subsidiary pharmacies are owned and managed by the license holder of 
the main pharmacy and they provide the full scope of pharmaceutical services to the 
public. Pursuant to Section 54 of the FMA, Fimea can decide to turn a subsidiary 
pharmacy to a pharmacy, if the turnover of the subsidiary pharmacy grows to a level 
which corresponds to at least half of the average turnover of private pharmacies in 
Finland. This can be done at earliest five years after the establishment of the subsidiary 
pharmacy. In case the turnover of the subsidiary pharmacy is larger than that of the 
main pharmacy, Fimea can issue the pharmacy license of the new pharmacy to the 
holder of the original license of the subsidiary pharmacy without an application 
process. 
Subject to a permit from Fimea, pharmacies can also establish pharmacy service points 
in sparsely populated areas (FMA 52a §). Service points are not required to be run by a 
pharmacist. Therefore, the pharmacy is required to have a plan regarding the selection 
of medicinal products available and the manner in which prescription are distributed 
drugs through the service point. The pharmacy must also have measures in place for 
ensuring drug safety. (FMR 21 §) 
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6.3.4. Pharmacy Fee 
In order to level out the differences in profitability between larger urban pharmacies 
and small pharmacies operating in sparsely populated areas, the state collects a 
pharmacy fee from all license holders. The fee is based on the Act on the Pharmacy 
Fee (Laki apteekkimaksusta 148/1946, Pharmacy Fee Act) and it is calculated based on 
the pharmacy’s turnover excluding value added tax and certain other exclusions. 
Turnover from in house pharmaceutical manufacturing, sales to public healthcare units 
and nicotine replacement products available outside of pharmacies is excluded. Also 
the sale of non-medicinal products is excluded but only up to an amount 
corresponding to 20 percent of total turnover after the exclusion of in house 
manufacturing and sales in healthcare units. (Pharmacy Fee Act 1a §) 
The pharmacy fee is progressive: Pharmacies with an annual turnover below EUR 
871,393 do not pay any fee. The percentage of turnover payable, starting at 6.10 
percent, increases in tiers with the highest pharmacy fee being for businesses with a 
turnover over the limit of EUR 6,243,857: For them the fee is EUR 537,406 and 11.20 
percent for turnover exceeding the limit (Pharmacy Fee Act 2 §). Turnover from 
subsidiary pharmacies, service points and online sales are included in the turnover. 
However, the Pharmacy Fee Act provides for different reductions from the turnover 
depending on overall turnover for the license holder and turnover from each 
subsidiary pharmacy. The aim for these reductions is to ensure that the pharmacist is 
not disincentivized from developing its subsidiary pharmacies and service points due to 
increases in the pharmacy fee. 
The effects of the pharmacy fee on the pharmacy market have been subject to 
significant debate. On one hand, the pharmacy fee is seen as an impediment to 
competition and one of the factors maintaining a higher price level for medicinal 
products. On the other hand, the pharmacy fee restricts larger pharmacies from 
engaging in aggressive price competition and ensures that all pharmacies across the 
country have more or less the same price level. Thus, smaller pharmacies in rural or 
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sparsely populated areas can maintain a price level that keeps the pharmacy business 
profitable.142 
During the 1990s and early 2000s there have been several calls and proposals to 
eliminate the pharmacy fee in Finland. In 1991, the Pharmaceutical Competition 
Committee recommended its discontinuation143, in 1997 the Working Group on 
Pharmaceutical Costs proposed that the government should remove the pharmacy fee 
“at its earliest convenience”144 and in 2007 the III proposed to abandon the pharmacy 
fee in stages145. However, these proposals only led to gradual adjustments in the 
pharmacy fee such as the exclusion of non-medicinal products from the calculation 
and measures to incentivize the upkeep of subsidiary pharmacies in sparsely populated 
areas. In its policy papers from 2003 and 2011, the Ministry of Social Affairs and Health 
highlighted the aim of a comprehensive pharmacy network which reaches also sparsely 
populated areas as one of the main priorities of Finnish policy concerning 
pharmaceutical care146. 
In recent years, the Finnish Competition and Consumer Authority (Kilpailu- ja 
kuluttajavirasto) has highlighted the problems which the pharmacy license system and 
pharmacy fee pose on competition147. The Ministry of Social Affairs and Health 
Committee for developing the pharmacy sector and other pharmaceutical care on the 
other hand has stated that the central aim of pharmaceutical care is related to public 
health and “therefore the competition aspect cannot be the primary starting point in 
developing [pharmaceutical] activity”. This does not exclude the possibility of 
promoting healthy competition through improving efficiency and quality. The 
Committee also found that the type of business entity does not necessarily have an 
impact on the quality and development of the pharmacy. However, it pointed out that 
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under the current license system pharmacies pay their taxes in Finland whereas the 
three largest pharmacy chains in Norway are under foreign control and in half of them 
the main shareholder is a holding company with its seat in a tax haven. The 
Committee’s proposal is to develop the pharmacy sector on the basis of the current 
framework of pharmacy licenses and pharmacy fees.148 
6.3.5. University Pharmacies 
The pharmacy privilege of the University of Helsinki dated back to the privilege issued 
to the Royal Academy of Turku in 1755. In 1953, the University of Helsinki was 
permitted to establish subsidiary pharmacies in selected large cities in Finland. These 
days the University of Helsinki is allowed 16 subsidiary pharmacies (FMA 52.3 §). Also 
the University of Eastern Finland has the right to run one university pharmacy in 
Kuopio (FMA 42 §). University pharmacies are not allowed to establish pharmacy 
service points but they can engage in online sale (FMA 52a.5 §, 52b §). The purpose of 
the pharmacy privilege is to provide a training facility for pharmaceutical education 
and research to the universities (FMA 42 §). They for example provide in house 
manufacturing of medicinal products to privately owned pharmacies. However, since 
the pharmacy fee collected from the universities is allocated from the state directly to 
the relevant university, pharmacies have become a significant source of income for the 
universities. Furthermore, the effective lack of a pharmacy fee gives university 
pharmacies a competitive advantage in the market.149 
6.3.6. Medicinal Products outside of the Pharmacy 
In 2005, Finland freed the sale of nicotine replacement drugs to retail stores and kiosks 
which also sell tobacco products (FMA 54a §). The reasoning for releasing these 
products to sale outside of pharmacies was that products which help citizens to quit 
smoking should be readily available to anyone who needs them. Furthermore, 
increased competition would bring down prices. Together these effects would reduce 
the threshold of attempting to quit. This would lead to cost-efficient improvements in 
public health and savings for the state. In considering the proposal, the legislator 
acknowledged the significance of guidance for the patient from pharmaceutical 
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professionals. However, the benefit of improved access, even where guidance was not 
available, was seen as sufficient reason to release nicotine replacement products for 
sale outside of pharmacies. Also, lack of pharmaceutical guidance and control was not 
seen to pose a significant risk in terms of drug safety.150  
The permit process for selling nicotine replacement products is similar to that of 
tobacco products and it is administrated by municipalities (FMA 54a.2 §). As a 
consequence of the 2005 reform, nicotine replacement products were also released 
from price control (FMA 37a §).  
6.3.7. Price Regulation and Reimbursement under the National Health 
Insurance System 
6.3.7.1. Wholesale Prices 
According to Section 37a of the Finnish Medicines Act the wholesale price of each 
medicinal product, including all rebates, must be the same for all pharmacies. 
Wholesale prices for medicinal products can be updated by the market authorization 
holders every two weeks to the university pharmacies and the Association of Finnish 
Pharmacies (Apteekkariliitto). In connection with Finland’s accession in the EEA, the 
requirement of a “reasonable wholesale price” was removed from the marketing 
authorization criteria151. However, price control is allowed under EU law for the 
purposes of national social insurance schemes. Thus, Finland applies a maximum 
wholesale price for all prescription drugs which can be reimbursed under the Finnish 
health insurance system.152  
Chapter 6 of the Finnish Health Insurance Act (Sairausvakuutuslaki 224/2004, FHIA) 
covers price control of medicinal products from wholesale prices to generic 
substitution and internal reference pricing. The Pharmaceuticals Pricing Board working 
under the Ministry of Social Affairs and Health decides on granting reimbursement 
status to each medicinal product under the health insurance system and on a 
reasonable wholesale price for the product (FHIA 6:1 §). This reasonable wholesale 
price works as a maximum price for the product and thus the wholesale price can 
                                                     
150
 HE 107/2005 p. 5–12. 
151
 HE 101/1993 p. 3. 
152
 HE 165/2002 p. 18. 
68 
 
always be set to be lower than that in order to meet competition from more 
affordable products. In assessing the reasonable wholesale price, the Board considers 
the costs of using the drug against the benefit for medical care in comparison with 
alternative care options. The price is benchmarked with corresponding products in 
Finland and in other EU Member States. Also the manufacturing, research and 
development costs can be taken into consideration when applicable. The Board also 
consults the Finnish Social Insurance Institution (Kansaneläkelaitos, KELA) during the 
process. The wholesale prices are set for a period of five years and for three years in 
case of a new active substance. The Board may also amend the reasonable wholesale 
price on its own initiative for example when a new cheaper generic product becomes 
available in the market or the medical purpose of use for the product becomes 
wider.153 
The requirement of the same wholesale price for all pharmacies was adopted in 2005 
in order to eliminate the effect of rebates on pharmacies’ practices in distributing 
medicinal products and carrying out generic substitution. The aim was to increase 
transparency in pricing and to ensure that consumers benefit from all rebates. 
According to the legislator, pharmacies should not receive indirect rebates in for 
example in the form of overpriced advertisement space or compensation for favorable 
shelf placement of specific products. The requirement of unified prices also eliminated 
volume and other rebates which until then had provided an advantage to larger 
pharmacies. Furthermore, the elimination of rebates also ensured that pharmacy 
personnel base their recommendations to the customer solely on the customer’s 
medical needs.154 
6.3.7.2. Pharmacy Profit Margin and Retail Price 
The retail price for consumers consists of the declared wholesale price, the pharmacy’s 
profit margin and value added tax. In Finland the maximum profit margin allowed for 
pharmacies is defined in Government Decree 713/2013 (Valtioneuvoston asetus 
lääketaksasta 17.10.2013/713). The profit margin limit is applied to all medicinal 
products and defined separately for prescription drugs and over the counter drugs. 
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The profit margin is calculated based on the wholesale price and consists of a fixed 
amount per package and a multiplier for the wholesale price. They are both defined for 
different wholesale price ranges. The multiplier is regressive: For example, for OTC 
drugs with a wholesale price below EUR 9.25 the fixed profit is EUR 0.50 and the 
multiplier is 1.5. For OTC drugs with a wholesale price over EUR 420.47 the fixed profit 
is EUR 47.68 and the multiplier is 1.125. Thus, the pharmacy’s profit margin percentage 
is higher for inexpensive products and lower for costlier ones (FMA 58 §, Decree 
713/2013 3 § and 4 §). In Finland, a lower rate for value added tax is applied to 
medicinal products. Value added tax for medicinal products is 10 percent (Finnish 
Value-added Tax Act (Arvonlisäverolaki, 1501/1993) 85a:1 § subsection 6). It should 
also be noted that due to the pharmacy fee, in practice the profit margin for certain 
medicinal products may not cover the distribution costs of the pharmacy. This is the 
case in particular for large pharmacies. 
6.3.7.3. Reimbursement under the National Health Insurance System  
The Finnish health insurance scheme reimburses the cost of prescription drugs which 
have been included in the reimbursement scheme in full or in part. Reimbursements 
are paid through the Finnish Social Insurance Institution, KELA, as expenses under the 
Finnish health insurance scheme which is funded in half with returns on the healthcare 
payments by the insured and in half by the state. In order to be included, a reasonable 
wholesale price needs to be defined for the medicinal product. (FHIA 5:1.1 §) 
Furthermore, granting reimbursement status for the medicinal product should support 
rational pharmaceutical care. Reimbursement status is not granted to products which 
have an insignificant value in medical care or the purpose of which is to treat illnesses 
with mild symptoms or which is used only temporarily.155 
Reimbursement is possible also for over-the-counter drugs which have been 
prescribed on medical grounds and which have reimbursement status (FHIA 5:1.2 §). 
Also costs for clinical nutritional preparations and basic ointments with reimbursement 
status can be reimbursed in case of a severe disease or chronic skin disease 
respectively (FHIA 5:2 §).  
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The basic rate of reimbursement is 35 percent of the retail price (FHIA 5:4 §). Special 
reimbursement is possible for severe and long-term diseases in two tiers. Under the 
higher special reimbursement medicine expenses are covered fully for costs exceeding 
EUR 3 per product. The lower special reimbursement rate is 65 percent of the retail 
price. (FHIA 5:5 §) If the total amount which the patient has paid for reimbursable 
drugs exceeds EUR 612.62 during one calendar year, the costs exceeding EUR 1.50 per 
drug are covered fully (FHIA 5:8 §)156. The Finnish social assistance scheme can cover 
medicine expenses which are higher than insignificant on social grounds (Finnish Act 
on Social Assistance (Laki toimeentulotuesta, 1412/1997) 7b § subsection 4).  
The medical conditions for which special reimbursement is available have been 
defined by government decree157. In order to qualify for reimbursement the patient 
must provide a doctor’s statement regarding the diagnosis and need for 
pharmaceutical treatment to KELA which also confirms the patient’s right to special 
reimbursement. For certain diseases with expensive treatments, the medical 
conditions and purposes of use for which basic reimbursement status is granted have 
been defined by government decree158. This can mean that reimbursement status is 
granted for a specific medicinal product only for patients whose disease has developed 
to a certain stage or who have a certain variant of the disease. In those cases the 
patient also needs to demonstrate by doctor’s statement that their disease and use 
correspond with those defined for reimbursement.159 
The marketing authorization holder of a medicinal product has a right to terminate the 
reimbursement status with prior written notice to the Pharmaceuticals Pricing Board. 
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The product’s reimbursement status, as well as its maximum wholesale price, ceases 
to apply at the beginning of the next quarter following termination.160 
6.3.7.4. Generic Substitution 
Finland adopted generic substitution in 2002. Before that, only generic prescription 
was possible. This meant that the doctor could prescribe a specific active substance 
instead of a medicinal product under a specific trademark. In those cases the 
pharmacy had an obligation to choose the least expensive readily available product. In 
practice, generic prescription was very rare and pharmacies did not keep a varied stock 
of generic medicinal products. Thus, the market share of generic drugs in Finland was 
low in 2002.161 
The adoption of generic substitution was justified with the aim to provide healthcare 
and pharmaceutical care in a rational manner. According to the legislator, 
reimbursement of medicinal products reduced the patient’s and the doctor’s incentive 
to prefer inexpensive products. This irrationality was enhanced through the lack of 
information which patients had regarding prices in the market. The legislator found 
that the pharmacy was the most rational instance for making the decision to provide a 
generic drug instead of the original medicinal product as pharmacies were in the best 
position to follow price levels and developments in the pharmaceutical market. In the 
government proposal for the legislative act to amend the FMA, the legislator argued 
that generic substitution would bring direct savings for consumers and to national 
health insurance and it would additionally increase price competition between the 
original medicinal product and generic drugs. The legislator cited successful savings in 
medicine expenses for example in Norway and Denmark. Generic substitution was 
seen to be in line with EU practice as well as the aims of maintaining competitiveness 
of the pharmaceutical industry and of promoting public health: Decreased medicine 
expenses would free up funds for financing the development of innovative medicinal 
products.162 
Fimea maintains a list of substitutable generic medicinal products and parallel 
imported medicinal products. Together with the original product they form a 
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substitution group which at minimum will comprise the original patented product and 
one generic product or parallel imported product (FMA 57 c §).163  
The pharmacy has an obligation to substitute the prescribed medicinal product to a 
generally available product within the substitution group with the lowest price or to 
one which costs up to EUR 1.50 more than the most inexpensive product where the 
product costs less than EUR 40. For products which cost over EUR 40 the price 
difference to the most inexpensive product can be up to two euros. The prices are 
updated on the first day of each quarter based on prior price notification by each 
marketing authorization holder. The lowest price, including value added tax, among 
products in the substitution group on that day will be applied as the lowest price for 
the substitution group during that quarter. (FMA 57 b §) In addition to providing 
information on the properties and proper use of the prescribed drug, the pharmacy 
has an obligation to advise the patient on the prices of the generic drugs in the same 
group (FMA 57.1 §). The pharmacy’s informational obligation regarding medicinal 
products and their prices also extends to over-the-counter drugs.164 
The price needs to be flexible in order to make it feasible for pharmacies to provide 
either the product with the lowest price or one with a price close to the lowest to 
customers without delay. Firstly, pharmacies are not obliged to immediately stock the 
cheapest medicinal product in the market if it is not readily available. Sometimes 
generic products of a specific manufacturer have the lowest price only for the time 
that it takes for other manufacturers to respond to the price reduction. When the 
wholesale prices are updated the product with the most inexpensive price can change 
and vary. It would be counterproductive to oblige pharmacies to always stock every 
possible generic product from each available manufacturer for the same original 
medicinal product. Instead, they will need to have a selection of the most common 
generic products available and they can order product with the absolute lowest price 
for customers who request it and are ready to wait for the product to be shipped.165 
The doctor prescribing the medicinal product is allowed to prohibit generic 
substitution on medical or treatment-related grounds. For example, the patient’s 
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allergy to one of the non-active substances in the generic product can establish 
sufficient medical grounds. In practice the requirement regarding treatment-related 
grounds is fulfilled in cases where the proper medical treatment of the patient 
warrants the concise use of a product from the same manufacturer with the same 
packaging, for example for patients with dementia or a mental health condition. Also, 
in line with the principle of self-determination the patient may prohibit generic 
substitution without stating any purpose for such decision. In these cases the 
pharmacy is not allowed to substitute the medicinal product to a generic one (FMA 57 
b.3 §). In many cases generic substitution can support the patient’s right to self-
determination. Firstly, the asymmetry between the pharmacy and the patient 
regarding prices is balanced trough the pharmacy’s obligation to inform the patient. 
Secondly, the patient’s willingness to accept pharmaceutical care increases as the 
threshold to purchase and use the product reduces with price.166 
6.3.7.5. Internal Reference Pricing 
Finland adopted internal reference pricing in 2008. Under this system, reimbursement 
from the Finnish health insurance is only granted up to a reference price. The chief 
reason for adopting reference pricing in Finland was to accelerate and widen price 
competition already established through generic substitution. Based on experiences in 
other European countries, generic substitution and reference pricing support each 
other. Drug costs were expected to grow due to aging population, the development of 
pharmaceutical care and new medicinal products and the increased use of 
pharmaceutical care in treating illnesses. Thus, the internal reference pricing system 
was seen as necessary to ensure the sustainability of drug reimbursements under the 
Finnish health insurance system.167 
The Pharmaceuticals Pricing Board decides on the establishment of a reference price 
group which includes products in the same generic substitution group168. The Board 
does not have discretion in the matter but all substitution groups in which the 
products fulfil the relevant criteria will also be subject to reference pricing: The 
reference price group must include at least one generic product and all medicinal 
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products in the group must have reimbursement status (FHIA 6:18 §). Thus, reference 
pricing is not applied for medicinal products for which only the original product and a 
parallel imported product are available.169 
The Board determines a reference price for the group for each yearly quarter based on 
prior price notifications by marketing authorization holders of the products in the 
group. The reference price will be the retail price, including value added tax, of the 
most inexpensive product added with EUR 1.50 for product under EUR 40 and with 
EUR 2.00 for products with a retail price of EUR 40 or more (FHIA 6:19 §). Thus, small 
differences in prices will not impact the level of reimbursement for the patient or the 
price covered by the patient. In connection with confirming the reference price, the 
Board decides a maximum wholesale price for the entire reference price group. 
Individual product inside the group can have any wholesale price below the maximum 
price. The incentive to keep prices low comes from the combination of generic 
substitution and reimbursement only up to the reimbursement level based on the 
reference price.170 
As in generic substitution, the patient has the right to forbid substitution to a lower 
price product. However, if the product is included in a reference price group, the 
patient is reimbursed only up to an amount based reference price. Furthermore, the 
price which the patient covers above the reimbursement level of the reference price is 
not included in the calculation of the patient’s yearly drug costs under Section 5:8 
FHIA. 
7. Legislative Framework of Pharmaceutical Distribution in Norway 
Two central legislatives acts regulate pharmaceutical distribution in Norway: the Act 
relating to medicines etc. called Norwegian Medicines Act and the Norwegian 
Medicines Pharmacy Act (Lov om apotek: apotekloven – apotl. 2. juni 2000 nr. 39, 
NPA). These acts outline the fundamental principles relating to pharmaceuticals, their 
production, distribution and use. There are several regulations based on the Medicines 
Act and Pharmacy Act such as the Pharmacy Regulation (apotekforskriften (26. februar 
2001 nr. 178)) and the Medicines Regulation (legemiddelforskriften (18. desember 
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2009 nr. 1839)) which cover the pharmacy sector and pricing of medicinal products in 
more detail. The Norwegian National Insurance Act (Lov om folketrygd: 
folketrygdloven – ftrl. lov 28. februar 1997 nr. 19, NNIA) is relevant to the field of 
pharmaceuticals as it defines the social subsidies relating to medical and 
pharmaceutical costs. 
7.1. Development of Pharmacy Law in Norway 
7.1.1. Background & History 
Also in Norway, pharmacies first functioned under a royal privilege, the first of which 
was issued in 1595 for a pharmacy in Bergen. Pharmacy became an independent 
profession in Norway based on a royal decree in 1672 which separated pharmacy from 
the medical practice and made the pharmacy privilege subject to inheritance. This 
decree formed the regulatory basis of the pharmacy privilege in Norway until the 
enactment of a Pharmacy Act in 1909.171 
As in Finland, the development of the Norwegian pharmacy system was influenced by 
prohibition in the 1920s and other social and scientific developments. The pharmacy 
system was discussed throughout the decades and also a state monopoly was 
proposed in the 1920s as well as after the Second World War. Inheritance of the 
pharmacy privilege was discontinued by 1954. In 1953, a state monopoly was 
established for import and wholesale of medicinal products in the form of the 
Norwegian Medicines Depot (Norsk Medisinaldepot, NMD). 172 
Due to its privilege based structure, though out its history one of the pharmacy 
sector’s priorities was to maintain privileges. During the 20th century and particularly 
after the Second World War the greatest change facing the pharmacy sector in Norway 
was that manufacturing of pharmaceuticals moved from pharmacies’ in house 
manufacturing to industrial manufacturing. This, along with the threat of proposals to 
reorganize pharmacies in the 1950s, 1960s and 1970s on the basis of public ownership, 
put pharmacists on the defence. Pharmacies needed to justify their existence on a 
privately-owned basis through emphasising their role as service providers taking care 
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of tasks which were best carried out in private pharmacies. The Norwegian Pharmacy 
Association also argued that private ownership incentivized efficiency in the sector. By 
the 1980s the trend in relation to public ownership had turned and thus the challenges 
facing the sector became different.173  
7.1.2. 1980s–1990s: Pressure for Change 
The role of pharmacies in providing information and guidance on medicinal products 
and their use as part of the healthcare system was highlighted from 1985 onwards 
when pharmaceutical guidance and counselling was permitted in pharmacies. This also 
increased the contrast between the business perspective and healthcare perspective in 
the discussion regarding the development of the pharmacy sector.174  
In the 1980s, the Norwegian pharmacy system was very similar to the Finnish system. 
Pharmacy ownership was subject to a personal license granted to a certified Master of 
Pharmacy.175 The Norwegian Board of Health Supervision (Statens Helsetilsyn) was 
responsible for drafting a national plan for the pharmacy network in which it 
determined the need for pharmacy licenses based on population and geographic 
factors.176 Free establishment, pricing and competition were considered incompatible 
with the interest of the state.177 
Norway also applied a yearly pharmacy fee. The fee amounted to 0–4 percent of the 
turnover for medicinal products. Smaller pharmacies and less profitable pharmacies 
could be granted relief from the fee. Pharmacies which were either making a loss or 
were not profitable could also receive pharmacy assistance. The aim of the pharmacy 
assistance was to ensure availability of pharmacy services in sparsely populated and 
rural areas. It also served to ensure the economic independence of pharmacies and to 
eliminate influence of other market actors in choices made in pharmaceutical care. The 
pharmacy fee was directed into a pharmacy fee fund from which pharmacy assistance 
was paid. The fond was also used for financing other measures within the pharmacy 
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and health sector. Approximately half of the pharmacies in Norway either received 
pharmacy assistance or had been granted relief from the fee.178 
The protected status which pharmacy owners had in the form of the license system 
and possibility to receive pharmacy assistance was based on the idea that pharmacies 
served a purpose within the healthcare system. Pharmacists saw the system as a way 
to ensure that the aims of pharmaceutical care were not compromised by short-
sighted profit seeking. However, in 1987 the Norwegian Competition Authority 
(Konkurransetilsynet, former Prisdirektoratet) issued a report in which it found that the 
system did not encourage efficiency. It found that pharmacy assistance left pharmacy 
owners unaccountable and ensured a steady minimum wage level for them regardless 
of the quality of management. The fact that the amount of pharmacy assistance was 
tied to pharmacists’ wage level meant that in negotiations with the Norwegian 
Association of Pharmacists the result was not critical to approximately half of the 
employer organization’s (Norwegian Pharmacy Association’s) members. Furthermore, 
the Competition Authority considered that interest groups were too deeply involved in 
decisions regarding pharmacy licenses and seniority was prioritized over efficiency. It 
found that the state should aim to correct these anomalies in the market and to 
promote competition.179 
In 1988, The Norwegian Association of Pharmacists published the report Pharmacy 
towards the year 2000 (Farmasien mot år 2000)180 as a response to the Competition 
Authority’s arguments. The report emphasized the need for pharmaceutical expertise 
in regulating and managing the sector. The report started a series of researches and 
committee reports regarding the pharmacy sector in the next ten years. Also the 
Norwegian Directorate of Health (Helsedirektoratet) which was responsible for 
pharmacy policy under the Ministry Social Affairs (Sosialdepartementet) also 
supported the basis for the existing license system. One of its central arguments was 
that the new tasks relating to drug safety and guidance required more resources from 
pharmacies and cooperation with other healthcare units, and short-sighted economic 
thinking could jeopardize their fulfilment. The Directorate of Health, the Norwegian 
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Association of Pharmacists and the Norwegian Pharmacy Association all saw the 
Competition Authority as an external actor which lacked the professional expertise to 
assess the pharmacy sector and its special features.181  
In the late 1980s, the need for pharmacy assistance from the fond exceeded the 
budgeted amount during several consecutive years. This resulted in increased pressure 
from the government to reduce costs. The Ministry Social Affairs started to move 
towards the opinion that the license system provided a readily distributed market in 
which competition did not work182. In order to avoid such situations in the future the 
Norwegian Pharmacy Association proposed that the funds from pharmacy fee fund 
would be used more effectively within the pharmacy sector. Under the system of the 
time, the state guaranteed pharmacy owners’ loans for acquisitions, new 
establishments and renovations. Thus, investments were subject to the control of the 
Norwegian Board of Health Supervision183. The Pharmacy Association argued that 
better management and use of the pharmacy fee funds for investments would 
improve efficiency. Better use of available technology would also increase efficiency. 
However, the Pharmacy Association also emphasized the special nature of the 
pharmacy business and the role of the pharmacy as an information and service 
provider. Their view was that the license system, pharmacy fee and pharmacy 
assistance ensured a nation-wide service network and worked towards better drug 
safety. Pharmacy professionals found that pharmacies could provide patients rational 
pharmaceutical care most efficiently, if the economic basis of the activity was ensured 
by law. This would allow pharmacies to carry out projects to promote drug safety and 
public health which would not be profitable in an ordinary business environment.184 
7.1.3. Law Reform of 2001 
7.1.3.1. Preparation 
Despite the pharmacy professionals’ efforts to argue in favor of the existing system, 
preparation of a comprehensive law reform was started in 1994. The Ministry of Social 
Affairs and Health (Sosial- og helsedepartementet) established two public committees, 
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named after their chairs, to discuss the pharmacy sectors and medicinal products. The 
first committee, called the Grund Committee, was to evaluate the reimbursement 
system under national social insurance. The second committee, called the Strøm 
Committee, reviewed the general framework and requirements for retail sale of 
medicinal products.185  
The committee reports were published in 1997186. The Ministry received a total of 89 
statements from interest groups commenting the reports. The Strøm Committee 
report was used as the basis for the government proposal Ot.prp. nr. 29 (1998–99). 
The law proposal was sent for comments in 1998 and discussed in the Parliament 
during spring 2000 and approved in March 2000187. 
The health policy objectives defined as the basis of the 2001 reform in NOU 1997:6 
corresponded with the aims defined in the national health policy plan at the end of the 
1980s188. According to the report, the primary objective of the Norwegian pharmacy 
system is to provide the best pharmaceutical service to the public. This requires that 
the pharmacy sector is developed together with other branches of healthcare. The 
sector should be organized in a way that ensures reasonable access to effective and 
high quality medicinal products at a low price which is consistent across the country. 
The special features of the pharmacy sector in contrast to other fields of business were 
taken into consideration in the reform. These included the role of pharmaceutical care 
as part of medical care and other forms of healthcare and as an alternative to them, 
the risk of misuse and adverse effects and the impact of drug costs on the patient.189 
The Strøm Committee discussed the ways in which competition on the pharmaceutical 
market derogated from a perfectly competitive market. Some of the factors were 
structural. The asymmetric information between patients and other actors in the 
sector weakens the patient’s negotiation position and makes their behavior irrational. 
Third party financing of purchases in the form of reimbursements from the national 
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social insurance scheme reduce the incentive of patients and doctors to choose the 
cheapest product. Due to these factors the Committee saw public supervision and 
guidance to be necessary in order to ensure the quality of medicinal products and 
pharmaceutical care. Furthermore, price control reimbursement policies could be 
designed to encourage price competition and to ensure consistent prices across the 
country.190 
At the end of 1995 there were 250 privately owned pharmacies, 78 subsidiary 
pharmacies and 1,250 pharmacy sales points in Norway. This was significantly less than 
in other Nordic countries. According to the Committee, a greater number of 
pharmacies was necessary in order to establish more competition. This would then 
lead to greater pressure for pharmacies to lower costs and work efficiently. The 
majority of the Committee saw the pharmacy license system as a barrier to entry into 
the market. Furthermore, the license policy and pharmacy assistance among other 
features of the existing system191 reduced the entrepreneurial risk in the sector and 
did not incentivize renewal and development. The only source of uncertainty in the 
sector was related to the development of the regulatory framework, pharmacy fee and 
profit margin control. On the other hand, the Committee acknowledged that 
pharmacies take on many professional tasks which can be in conflict with their 
economic interests either voluntarily or required by law.192 
The Strøm Committee was divided on how the establishment of pharmacies should be 
organized. Six of its members193 were of the opinion that there were no strong 
economic or health policy arguments that a public authority should decide on the 
number and location of pharmacies. Their view was that drug safety and other 
professional standards could be ensured also within a system based on free 
establishment. The other six members194 disagreed and found that the establishment 
of pharmacies should be subject to regulation due to the pharmacies’ role as 
information and service providers. Furthermore, free establishment would not ensure 
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a comprehensive pharmacy network in sparsely populated areas. They also argued 
that the price elasticity of pharmaceuticals was very inelastic and thus competition 
would not reduce prices in any significant manner.195 
7.1.3.2. Main Objectives and Changes 
One of the aims of the reform was to change the license system so that more 
pharmacies could be established in Norway. In the Government proposal Ot.prp. nr. 29 
(1998–1999), the Ministry of Social Affairs and Health argued that pharmacy sector has 
not renewed itself in the same pace as other institutions in society. Any changes in the 
sector had been based on the existing values and opinions of the pharmacy profession. 
The Ministry’s view was that the sector had not been subject to significant impulses for 
change and renewal.196 
The Strøm Committee’s proposal of free establishment would permit pharmacy chains. 
The Committee argues that pharmacy chains would have a stronger negotiation 
position towards wholesale companies and that this would improve pharmacies’ ability 
to negotiate lower prices. The Strøm Committee’s proposal of free establishment was 
not adopted as such. Ownership was made possible for individuals without a degree in 
pharmacy and to corporations. However, each pharmacy was to be managed by a 
Master of Pharmacy. Pharmacy ownership and management were separated into two 
different license processes. After the reform, pharmacy chains were allowed. By 
promoting flexibility in ownership, the legislator aimed at increased development, 
competition and efficiency in the pharmacy sector.197  
The reform also updated safety and quality criteria to fit the new framework where 
pharmacies were not owned by pharmacy professionals. The reform also provided for 
special means for the public authorities to ensure that the pharmacy network would 
cover sparsely populated areas.198 
The Strøm Committee had discussed the sale of non-prescription drugs outside of 
pharmacies. The Committee was split on the matter as were the interest group 
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statements received during consultation. At this stage the government did not propose 
to release over the counter drugs for sale outside of pharmacies.199 
The 2001 reform introduced generic substitution in Norway as a means to increase 
price competition. However, the reference price system was left unaltered pending 
further evaluation.200 
7.1.4. Development of Pharmacy Law after 2001 
The Norwegian Medicines Act and the Norwegian Pharmacy Act have been amended 
several times since the 2001 reform. These amendments have mainly been introduced 
in order to develop individual topics relating to medicinal products and the pharmacy 
sector and to resolve smaller problems arising from the application of the new Acts. 
The restrictions on pharmacy ownership were specified in 2002 based on the 
Government proposal Ot. prp. 61 (2000–2001) in order to ensure competition and 
prevent circumventions to ownership restrictions201. This amendment also imposed an 
obligation to wholesale companies to provide price and sales data to supervising 
authorities for use in evaluating the success of price control measures202. The 
amendment also dicontinued the pharmacy fee system. The Ministry of Social Affairs 
and Health was of the opinion that the pharmacy fee caused distortions in 
competition. The pharmacy fee was replaced with a neutral sales fee on medicinal 
products which is covered by pharmacies in the wholesale price and charged from 
wholesale companies.203 
After the 2001 law reform and removal of the pharmacy fee, the Ministry entered into 
agreements concerning pharmacies in sparsely populated areas with the largest 
pharmacy chains in Norway. Under the agreements, the pharmacy chains undertook to 
establish and maintain pharmacies in municipalities where an earlier main pharmacy 
had discontinued its business. The framework was in place between 2001 and 2011 
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after which the scope of the pharmacy network has been determined on market 
conditions.204 
The Government proposal Ot. prp. 29 (1998–1999) stated that promotion and 
advertisement of medicinal products should be investigated and clarified in the future. 
Marketing and advertisement were addressed with Ot. prp. 55 (2001–2002) which was 
enacted in 2003.205 
In 2003, a reference price system was introduced. Its aim was to support the 
functioning and efficiency of generic substitution. In connection with the reference 
price, also the rebates in wholesale prices given to pharmacies were also regulated in 
order to ensure that customers would benefit from the rebate206. The market share of 
generic products within prescription drugs in 2003 was approximately 15 percent. The 
law proposal aimed at introducing measures to increase price competition in advance 
of the upcoming breakthrough of generics in the pharmaceuticals market. Introducing 
such measures any later, after generic products had established their role in the 
market, could cause a significant market disruption.207 The means for the government 
and the Ministry of Health and Care Services (Helse- og omsorgsdepartementet) to 
regulate prices and manage the reference price system were specified further with 
another amendment in 2008.208  
The Norwegian Pharmacy Act was amended also in 2009 in order to improve the act 
based on experiences gained since the law reform. For example, restrictions on 
opening hours were removed from weekdays, regional restrictions on distance orders 
were removed, marketing restrictions of drugs inside the pharmacy were simplified 
and practical issues within the license processes were resolved.209 
7.2. Main Features of the Norwegian Pharmacy System 
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7.2.1. Pharmacy Ownership and Management 
7.2.1.1. Pharmacy License 
In Norway, ownership of a pharmacy business is subject to a pharmacy license from 
the Norwegian Medicines Agency (NPA 1:4 ja 2:1). However, the pharmacy license is 
not personal in the sense that it needs to be issued to an individual. In addition natural 
persons, the license holder can be a company or corporation. A single company or 
person can hold several pharmacy licenses and thus pharmacy chains are permitted in 
Norway. 
The applicant has to prove sufficient economic means to engage in the pharmacy 
business in an economically responsible manner and in accordance with the 
requirements set by law and regulations. Due to the standards and special service 
obligation applied to retail distribution of medicinal products, the above requirement 
also includes providing unprofitable services to customers. The applicant must also 
prove with sufficient likelihood that the pharmacy business will reach a high enough 
volume in order to sustain the minimum level of specialization and drug manufacturing 
standards required by law (NPA 2:2 subsections a and b). The pharmacy permit can 
include special conditions regarding services, opening hours and other factors in order 
to ensure local or regional fulfilment health policy objectives. For example, the Agency 
can set an obligation to maintain a subsidiary pharmacy or pharmaceutical sales point. 
However, this kind of enforcement to run a business is an exceptional measure applied 
only in cases fulfilling specific geographic, demographic and economic criteria relating 
to pharmaceutical services in the area. In these cases the Agency can compensate the 
license holder with public funds.210 
Pharmacy ownership is restricted to individuals who are not engaging in industrial 
pharmaceutical manufacture and who do not have the right to prescribe medicine to 
patients. Similarly, companies which engage in industrial pharmaceutical manufacture 
or in caring diseases or which have a person with a prescription right in their 
management cannot be granted with a pharmacy license. The NPA extends this 
restriction to indirect ownership. This is to avoid any conflict of interest between the 
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commercial benefit of selling medicinal products and servicing the patients’ medical 
needs (NPA 2:3). A pharmacy license can be granted to a municipality, regional 
administration or a company owned by either of the aforementioned on special 
grounds (NPA 2:4).211  
The pharmacy license usually gives the license holder a right to establish or own a 
pharmacy within a specific municipality (NPA 2:7). The license allows the license holder 
change the location of the pharmacy within the municipality. As a rule, in case the 
pharmacy owner wishes to move the pharmacy into a facility located in another 
municipality, even if it is nearby, a new pharmacy license is required. However, 
according to clause 3 of the Norwegian Pharmacy Regulation (apotekforskriften (26. 
februar 2001 nr. 178), NPR) the pharmacy license can define an alternative 
geographical area in case it is necessary due to the natural customer base of the 
pharmacy. 
The conditions under which the pharmacy license can be revoked are similar in Norway 
as in Finland. The pharmacy license can be revoked for example if professional 
standards under Section 2:8 of the NPA are not met or if the license holder no longer 
meets the eligibility criteria under Sections 2:2 and 2:3 NPA. Other conditions include 
neglect of reporting obligations required by law or decision of a public authority, 
failure to cooperate with supervising authorities and closing of the pharmacy due to 
danger to health or safety. Revocation is also possible if, under prevalent conditions, 
the license holder becomes legally incapable of pharmacy ownership. (NPA 2:8 §) 
Sections 2 and 3 of the Norwegian Pharmacy Act authorize the Ministry of Health and 
Care Services to further regulate the right to receive a pharmacy license in case it is 
necessary from a competition policy viewpoint and limit the right in case it is necessary 
for the responsible distribution of professional pharmacy services in the country. 
Clause 13 of the NPR caps the market share of pharmacy ownership to 40 % of the 
total turnover of non-hospital pharmacies in the country. This requirement can be 
overlooked in order to ensure sufficient supply of medicinal products in the area. 
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7.2.1.2. Management Permit 
Each pharmacy in Norway must be run and managed by a pharmacist. Management is 
subject to a management Permit granted by the Norwegian Medicines Agency (NPA 
1:4 §, 3:1 §). The management permit concerns the person who is responsible for the 
operative management of a specific pharmacy and possible subsidiary pharmacies and 
it requires the permit holder to be personally present and involved in the pharmacy in 
order to carry out the day to day running of the pharmacy business (NPR 15 §). Prior to 
receiving the management permit, the pharmacy license holder must prove that the 
pharmacy facilities meet the requirements for running a pharmacy establishment and 
that the pharmacy has the required capability for in house manufacture of medicinal 
products (NPA 3:3 §). 
The pharmacist is responsible for ensuring that the pharmacy business is carried out in 
accordance with relevant legislation, regulations, decisions of public authorities and 
the requirements of good pharmacy practice and manufacturing practice for medicinal 
products (NPA 3:6.1 §). The pharmacists must follow the pharmacy owner’s 
instructions to the extent that they are in line with relevant professional standards 
(NPA 3:6.2 §). The pharmacy license holder decides all significant and extraordinary 
matters concerning the pharmacy as well as hiring and dismissal of pharmacy 
personnel based on the recommendations of the pharmacist, provided that the 
pharmacy owner has not authorized the pharmacist to make such decisions 
independently. (NPA 3:6 §). 
One person can hold only one management permit at a time. The pharmacist must 
meet certain eligibility criteria concerning the applicant’s professional skills and civic 
constitution. The pharmacist must hold a certified Master’s degree in Pharmacy, a 
minimum of two years’ work experience after graduation and the competency of a 
pharmacist provisor. The Norwegian Medicines Act also requires a clean criminal 
record as well as suitability for managing a pharmacy business (NPA 3:2 §). The 
applicant is unsuitable in case they have been convicted to prison for an economic or 
financial crime for 3 years or more, in case of serious substance addiction and 
irresponsible exercise of their rights and obligations as a pharmacist (NPR 17 §). 
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7.2.2. Subsidiary Pharmacies and Pharmaceutical Sales Points 
The pharmacy license can also include a right to own and the management permit can 
include a right to run a subsidiary pharmacy (NPA 3:4 §). The pharmacist managing the 
pharmacy is accountable the subsidiary pharmacy and its functioning. However, the 
pharmacist has an obligation to designate a person who is responsible for managing 
the subsidiary pharmacy. This person must be qualified as a pharmacist provisor. 
Pharmacy license holder can also have a license to maintain a pharmaceutical sales 
point in areas without a pharmacy. The requirement is that there is no pharmacy or 
subsidiary pharmacy within 10 kilometres of the sales point (NPA 2:7.1 § subsection a). 
The pharmaceutical sales point can only distribute over-the-counter drugs and other 
products which are not subject to prescription or classified as medicinal products (NPR 
57 §). The pharmacy is required to make a list of products available at the sales point in 
cooperation with the municipal doctor (NPR 58 §). 
7.2.3. Medicinal Products outside of the Pharmacy 
In 2003 the Norwegian Ministry of Health and Care Services released certain OTC drugs 
for sale outside of pharmacies (NMA 16.4 §). The government regulation on the sale of 
non-prescription drugs (forskrift om omsetning av reseptfrie legemidler, 14. august 
2003 nr. 1053, generally called the LUA regulation (legemidler utenom apotek)) 
provides detailed regulation on the distribution of medicinal products in retail stores. 
For example, medicinal products must be placed so they are distinguished from other 
products and are not available to children under the age of 18 (LUA regulation 10 §). 
According to the regulation, the Norwegian Medicines Agency can restrict the number 
or size of packages which can be sold to an individual customer (LUA regulation 11 §). 
Products available outside of pharmacies include traditional herbal medicinal products, 
nicotine replacement products and specific non-prescription drugs listed by the 
Norwegian Medicines Agency (LUA regulation 1 §). The aim of permitting sale of 
certain medicinal products outside of pharmacies was to improve access to medicine 
and to increase price competition. 
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7.2.4. Price Regulation and Reimbursement under the National Health 
Insurance System 
7.2.4.1. Wholesale Prices 
One of the state’s central aims concerning medicinal products is to ensure that 
medicinal products are affordable to citizens. As in Finland, citizens can have expenses 
for pharmaceuticals reimbursed by the Norwegian national insurance scheme 
(folketrygden), regulated by the Norwegian National Insurance Act (NNIA). Thus, it is in 
the interest of the state to influence drug prices for two reasons: Firstly, low prices 
ensure that as many citizens as possible will purchase their medicine without need of 
assistance. Secondly, when prices for medicinal products are low, the state’s expenses 
under the national insurance scheme remain reasonable. 
Prices for medicinal products have been regulated in Norway since 1928. In connection 
with Norway’s accession in the EEA, direct price control has been applied only for 
prescription drugs from 1995 onward212. Thus, unlike in Finland, prices are limited 
irrespective of the drug’s reimbursement status. Price control for medicinal products in 
Norway includes a cap for the price on all prescription drugs and mechanisms to 
stimulate further price competition. Since veterinary medicinal products and OTC 
drugs can be priced freely, the state attempts to influence their prices through 
alternative means. One of the legislator’s aims in liberating pharmacy ownership in 
2001 was to lower consumer prices through enabling synergies for pharmacy chains 
and through increased competition. Also the sale of certain non-prescription drugs 
outside of pharmacies under the LUA-regulation is expected to increase price 
competition for OTC drugs.213 
Price control in Norway covers the wholesale and retail level of the value chain for 
medicinal products. Importers and wholesale companies negotiate their prices with 
pharmaceutical manufacturers freely to establish the wholesale purchase price 
(grossistenes innkjøpspris, GIP).214 Price control for prescription drugs is covered in 
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Section 6 of the NMA and chapter 12 of the NMR. The Norwegian Medicines Agency 
determines the highest permitted wholesale price for each medicinal product 
(apotekets innkjøpspris, AIP, also referred to as maksimal AIP). In its deliberation the 
Agency takes into consideration the market price of the medicinal product in Sweden, 
Finland, Denmark, Germany, the United Kingdom, Netherlands, Belgium and Ireland. In 
special cases the AIP price can be set to be higher than in the reference states if this is 
required to ensure that the product remains available in Norway. The value of the 
product within medical care, the price level of corresponding products and 
manufacturing and development costs are also taken into consideration in determining 
the AIP. The Norwegian Medicines Agency readjusts the wholesale price for the most 
commonly sold products on a yearly basis. For other products the AIP price can be 
reviewed upon request of the marketing authorization holder or on the Agency’s own 
initiative. As a rule, such reviews are not made more frequently than one year after the 
latest review.215 
7.2.4.2. Pharmacy Profit Margin and Retail Price 
The profit margin which pharmacies can charge for prescription drugs is capped. The 
Norwegian Medicines Agency determines the maximum profit margin for pharmacies 
which consists of a fixed amount in NOK and a percentage of the wholesale price (NMR 
12:3 §). Thus, the AIP price of the medicinal product and value added tax determine 
the consumer price (apotekets utsalgspris AUP) together. In Norway, the general value 
added tax, which is 25 percent, is applied to medicinal products216. 
The Agency reviews the maximum profit margin every four years. From 1 January 2014 
onwards, the maximum profit for the sale of an individual medicinal product package 
has been as follows. The fixed amount for each package is NOK 25.00. The portion of 
profit determined as a percentage of the wholesale price has been divided in two parts 
and stands at seven percent for the first 200.00 Norwegian krone and three percent 
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for the remaining part of the AIP. For prescription drugs in classified in groups A and 
B217 the fixed portion of profit is NOK 10.00.218 
During the early 1990s drug expenses were growing at a significant pace. The Strøm 
Committee saw this as a result of a general increase in the price level and increased 
drug consumption and especially as a result of a transition to new, costlier 
pharmaceuticals. There had been calls for a greater level of regression in the maximum 
profit margin and this had been implemented in 1992. Additionally, the profit margin 
was amended in 1995 to cover fixed costs more effectively while reducing the 
percentage portion in the calculation. The profit margins were also cut in 1996 and 
1997.219 
The Norwegian Medicines Act forbids rebates which are not granted at the time of 
purchase (NMA 6.1 §). However, rebates as are not forbidden as they can work 
towards lower retail prices. The state has ensured that rebates which pharmacies 
receive on wholesale prices are directed to the benefit of the consumer under a profit 
allocation system (gevinstdelningssystemet)220. In case pharmacy manages to 
negotiate a rebate on the maximum wholesale price, a minimum of 50 percent of the 
difference between the maximum wholesale price and the negotiated price should be 
allocated as a rebate on the consumer price (NMR 12:3.2 §). The pharmacy can keep 
the remaining portion of the rebate which increases the pharmacy’s profit margin. This 
incentivizes the pharmacies to negotiate rebates from wholesale companies and 
ensures that rebates from wholesale companies are visible in retail prices.221 For 
example rebates based on purchase volume at the end of the year are not allowed as 
the benefit from the rebate is provided to the pharmacy as a price refund. When 
rebates are defined beforehand, they impact the profit margin of the pharmacy and 
the retail price for the consumer directly. Furthermore, this increases transparency in 
pricing and facilitates pharmacies’ price comparison and competitive bidding between 
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suppliers.222 The profit allocation system is not applied to prescription drugs subject to 
internal reference pricing.223 
7.2.4.3. Reimbursement under the National Health Insurance System  
In Norway, citizens’ medicine expenses have been kept at a reasonable level through 
reimbursements for prescription drugs from the national insurance scheme since 
1953.224 For this purpose prescription drugs have been divided into products subject to 
standard reimbursement which in Norway are called drugs under blue prescription 
(legemidler på blå resept) and to other prescription drugs (hvit resept). Drugs under 
blue prescription are covered in the Regulation on Assistance for Covering Expenses 
for Important Medicines (Forskrift om stønad til dekning av utgifter til viktige 
legemidler mv. (blåreseptforskriften) (28. juni 2007 nr. 814), Blue Prescription 
Regulation, BPR). 
The Norwegian reimbursement system includes similar requirements for prescription 
status as the Finnish one. The Norwegian Medicines Agency maintains a 
reimbursement list which includes all drugs under blue prescription that is medicinal 
products which have been preapproved for reimbursement. All patients, whose 
symptoms match with the purpose of use for the preapproved prescription drug  and 
whose use of the product is long-term, that is three or more months per year, are 
entitled to partial or complete reimbursement for their medicine expenses (BPR 2 §). 
Preapproved reimbursement has also been enabled for certain contagious diseases. In 
addition to medicinal products, certain nutrition supplements and accessories which 
are used in connection with medical treatment or are necessary as a result of illness 
are also covered. Examples include catheters, syringes and insulin pens (BPR 5–6 §).225  
Sometimes a patient is not entitled to preapproved reimbursement for a necessary 
prescription drug due to the nature of her symptoms or because the necessary 
medicinal product is not on the reimbursement list. For such cases, the doctor 
prescribing the drug can apply for special reimbursement under blue prescription on 
behalf of the patient (BPR 3 §). 
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Reimbursements for medicine expenses are covered at the time of purchase by the 
Norwegian Health Economics Administration (Helseøkonomiforvaltningen HELFO) 
which is works under the Norwegian Directorate of Health (Helsedirektoratet). Each 
patient pays 38 percent of the retail price but only up to NOK 520.00 per prescription. 
Children under 16 years of age, war invalids and individuals living on minimum pension 
are exempt from payment and their medicine expenses are reimbursed in full. 
Medicine expenses are also covered in full under the national insurance scheme for 
certain illnesses and contagious diseases (BPR 7 §). 
In case the necessary prescription drugs are not subject to blue prescription or special 
reimbursement the patient will pay the full price of the product. However, in case the 
medicine expenses exceed NOK 2185 during the year, the patient is entitled to a 
reimbursement of 90 percent on remaining expenses. Patients with high drug costs can 
also receive assistance for their expenses on social grounds (NNIA 5:22 §).226 
7.2.4.4. Generic Substitution 
From 1987 onwards doctors had an obligation to prescribe the medicinal product with 
the lowest price and from 1991 onwards the obligation was to prescribe the most 
inexpensive generic product. This increased the market share of generic products for 
certain drug groups. However, generic prescription did not ensure price competition 
effectively as doctors’ knowledge of price developments was limited.227 In connection 
with the 2001 law reform, Norway adopted generic substitution. Pharmaceutical 
personnel can substitute the original medicinal product prescribed by a doctor to a 
parallel imported product or less costly generic product (NPA 6:6 §). They also have an 
obligation to inform the patient about lower price generic products (NPA 6:4 §). The 
Norwegian Medicines Agency maintains a list of substitutable products (byttelisten) 
which is updated twice each month.228 Medicinal products which are substitutable 
with each other form a substitution group (byttegruppen). Similarly as in Finland, the 
chief aim for adopting generic substitution was to lower drug prices and 
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reimbursement costs for the state.229 Parallel import has been allowed in Norway since 
1995 and parallel imported products are included in generic substitution230. 
In Norway, doctors can indicate in the prescription that generic substitution is not 
allowed on medical grounds (NMR 12:16 §). This practice is similar to the medical 
grounds on which generic substitution can be restricted in Finland. The patient has a 
right to forbid generic substitution. However, in that case the product is only 
reimbursed up to the price of the least expensive product in the substitution group or 
in accordance with the reference price (BPR 8 §). 
7.2.4.5. Internal Reference Pricing 
In 1993 Norway introduced a reference price system for those medicinal products for 
which their patent had expired. Under this system, a maximum price was set for the 
reimbursement granted for certain substitution groups. This resulted in the prices 
within these drug groups falling to the level of the reference price. However, in 
connection with the 2001 law reform, the reference price system was discontinued on 
the grounds that its administrative costs were higher than the achieved savings.231 
In 2005 internal reference pricing was reintroduced to support price competition 
established through generic substitution. Since 2005, reference prices have been 
lowered several times. In connection with its proposal to reduce reference price levels 
and pharmacy profit margins in 2013, the Ministry of Health and Social Affairs found 
that the Norwegian reference price system and generic substitution had been 
successful in decelerating the increase of pharmaceutical prices.232 
The Norwegian reference price model aims at ensuring effective pharmaceutical care 
and mitigating reimbursement costs for the state. The Norwegian Medicines Agency 
can decide to set a reference price for a particular substitution group and determines 
to which generic products the reference price is applied. As a prerequisite for setting a 
reference price, the products must be on the Agency’s substitution list and at least one 
generic product must be competing steadily with the original product in the Norwegian 
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market (NMR 12:14 §). The contrast to Finland is that in Norway the reference price is 
not necessarily applied immediately when a new generic product enters the market as 
steady competition must first be established. 
HELFO reimburses drug costs up to the reimbursement based on the reference price. 
In case a more expensive product is chosen, the patient has to cover any amount 
above the reimbursement level at reference price. This amount is also not considered 
part of the patient’s overall yearly drug expenses. (NMR 12:16.1 §, 12:16.3 §, NNIA 8.3 
§) However, in case the doctor prescribing the original or other more expensive 
product has prohibited generic substitution, reimbursement is granted on the basis of 
the actual price paid for the medicinal product (NMR 12:16.2 §).  
The reference price is calculated by making two to three percentage cuts to the price 
of the original medicinal product. The maximum wholesale price of the original 
product is usually used as the starting point. The reference price is relatively lower for 
substitution groups where the total value of sales within the group was NOK 100 
million or more during a 12-month period within two years before generic competition 
was established.  For these substitution groups the first cut is made as a 35 percent 
reduction from the original price and it takes effect at the moment generic 
competition begins. The second cut amounts to an 81 percent reduction from the 
original price and it is made six months after competition has been established. For 
other substitution groups the first cut is 35 percent and the second cut is 59 percent. A 
third cut can be made 12 months after the second cut based on the sales volume of 
the substitution group. (NMA 6.2 §, NMR 12:15.1–12:15.4 §)233  
8. Legal Principles in Preparatory Materials of Pharmacy Legislation 
This section highlights the legal principles and fundamental rights which the Finnish 
and Norwegian legislator have taken into account in their choices regarding their 
respective pharmacy systems. The findings are based on an examination of the 
preparatory materials for Finnish and Norwegian pharmacy legislation in relation to 
the main features of the system as described in sections 6 and 7. 
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The following central principles play central a role in the argumentation provided in 
preparatory works: the right to health and the patient’s right to self-determination. 
The following chapters will outline their role in the pharmacy sector. 
However, other fundamental rights have also been referenced in the travaux 
préparatoires. For example, the Finnish legislator has reviewed entrepreneurial 
freedom under Section 18 of the Finnish Constitution in the context of the pharmacy 
sector. In its evaluation of the impacts of legislative measures such as subjecting 
certain activities to a permit process, the legislator has referred to opinions of the 
Committee for Constitutional Law. Permit processes are justified for example in order 
to ensure health or safety. In regard to generic substitution, the legislator on the other 
hand evaluated whether changes in the reimbursement system restricted 
entrepreneurial freedom of pharmacies and pharmaceutical companies. The legislator 
concluded that generic substitution did not prevent the sale of specific products and 
that the economic impact of the amendment on pharmacies and industry actors was 
not so significant as to constitute a limitation of their fundamental rights.234 
8.1. Right to Health 
The substance of the right to health is multi-faceted and has a wide scope. Many 
different legal principles and policy aims can work towards the fulfilment of the right 
to health. For example, Section 7.1 of the Finnish constitution has been interpreted to 
support measures promoting public health in connection with Section 19 of the 
Constitution235. Considerations relating to the right to health within the pharmacy 
sector can be grouped under the following themes: equal access to healthcare, 
allocation of resources and drug safety. 
These themes and the more specific principles described in connection with them have 
not been derived from the right to health. I see the right to health to be on a deeper 
level of sedimentation within the legal system than perhaps the legal principle of equal 
access to healthcare. The right to health through its standing in international 
conventions and its impact on other areas of law, for example criminal law, provides 
institutional support to the principle of equal access to healthcare. Furthermore, in 
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working closer to the surface of the legal system, the principle of equal access to 
healthcare is useful for determining the substance of the right to health. The themes of 
drug safety and allocation of resources, on the other hand, are reflections of the right 
to health in the factual context of the pharmacy sector and the principles are legal 
principles which are related or overlap with the right to health. 
8.1.1. Equal Access to Healthcare 
As described in section 4.4.2, equal access to healthcare is provided for in several 
international treaties regarding social human rights. Both the Finnish and the 
Norwegian legislator places pharmaceutical care within the field of healthcare by 
acknowledging its role within medical care and its potential as an alternative to 
medical care236. The impact of the principle of equal access is evident in many ways in 
the preparatory works of pharmacy law in Finland and Norway. 
The state needs to take many practical matters into consideration in order to ensure 
equal access to healthcare. Equal access to healthcare is multi-faceted in its substance. 
Therefore, different mechanisms for ensuring equal access within the pharmacy sector 
are discussed separately under the following topics: affordable medicine, pharmacy 
service network and customer service. These practical factors also reflect different 
aspects of the principle of equal access. 
8.1.1.1. Affordable Medicine 
The principle of equal access to healthcare requires the state to apply a standard of 
equality within the health sector. According to the Finnish and Norwegian legislator 
one central factor for ensuring equal access in practice is the price of medicinal 
products. The state has an obligation to ensure that the pharmacy system works 
towards lower consumer prices and restrains the trend of increasing prices for 
pharmaceuticals. Price control of prescription drugs is a practical way of ensuring a 
reasonable price level. 
In its call for efficiency within the pharmacy sector in connection with the 2001 law 
reform, the Norwegian legislator did not only consider drug reimbursement costs and 
pharmacy assistance costs of the state. The legislator argued that reduced costs within 
the pharmacy sector and increased competition would also lead to lower prices for 
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consumers. Also, by introducing generic substitution and reference pricing, the Finnish 
and the Norwegian legislator both adopted measures which had successfully reduced 
prices in other countries. These measures were not justified based on a political aim to 
improve the position of the manufacturers of generic products. Such a goal existed but 
only in order to serve the aim of lower prices on medicinal products and thus improved 
access to pharmaceutical care. 
In social law and health law, the principle of need plays a central role in defining the 
substance of equal access. This principle is evident in considerations regarding 
reimbursement of drug costs in Finland and Norway. Firstly, the principle of need is 
central to the very existence of the reimbursement system. Illness is something which 
can affect any citizen regardless of their actions. Individual citizens should not be faced 
with unreasonable financial implications due to the price of the medicinal products 
required to treat an eventual illness. In case of a long-term disease or serious illness, 
the individual has a particular need for medicinal products. Therefore, the state should 
provide financial assistance for covering drug costs in the form of reimbursements 
under a social or health insurance scheme. 
Secondly, the principle of need is employed in the criteria and decision-making for 
granting reimbursement status for medicinal products. The legislator refers here to 
ensuring rational pharmaceutical care. Since the funds available for reimbursement are 
limited, the scope of reimbursement needs to be limited with use of the principle of 
need. Therefore, there are certain criteria in place for grating reimbursement status 
for medicinal products and for limiting the purpose of use for which reimbursement is 
possible. For example, products which are used short term pharmaceutical care or for 
mild symptoms are excluded from reimbursement. Special reimbursement in case of 
serious illness or expensive necessary treatment also reflects the principle of need. 
8.1.1.2. Pharmacy Service Network 
The availability of pharmacy services and medicinal products is a significant practical 
requirement for the equal access to pharmaceutical care. Due to the geography and 
demographic features of Finland and Norway, this question has been a particular 
challenge for the legislator in both countries. The means with which the reach of the 
pharmacy network has been ensured in sparsely populated areas is different in the 
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two countries. A comparatist would say that the institutions chosen to resolve the 
question of equal access to medicine are different. 
The Finnish system relies on its pharmacy license and pharmacy fee systems. The 
former provides the state with means to determine the location of pharmacy services. 
Pharmacy fees on the other hand work as an income distribution model for 
pharmacies. The progressive structure of the fee ensures that larger pharmacies 
cannot drive prices down to a level where small pharmacies in scarcely populated 
areas no longer are profitable. In maintaining the pharmacy fee, the Finnish legislator 
has made a valuation regarding the substance of equal access to healthcare: the aspect 
of availability to services has been highlighted at the expense of the aspect of 
affordable medicine. 
In Norway, the pharmacy fee was abolished in the 2001 reform and ownership was 
made available to others than individuals with a master’s degree in pharmacy. 
However, this does not mean that the aim of a comprehensive pharmacy network as 
abandoned. The reform was introduced in order to increase the number of pharmacies 
in all of Norway. The state used special measures, for example direct agreements with 
pharmacy owners, to ensure the availability pharmacy services in sparsely populated 
areas. 
The Norwegian legislator also aimed at improved availability in releasing certain over-
the-counter drugs to sale outside of pharmacies, as did the Finnish legislator in relation 
to nicotine replacement products.  
8.1.1.3. Customer Service 
The state is successful in ensuring rights only if the relevant right is fulfilled in 
practice237. Access to healthcare is only the first step as the actual care must also 
correspond with the patient’s needs238. In the context of pharmaceutical care this 
means firstly that the patient is provided with the appropriate medicinal product in 
relation to their specific need. Secondly, pharmaceutical care is only successful if the 
patient then uses the medicinal product correctly. Thirdly, equal access to healthcare 
also spans preventive care. The fulfilment of all three factors is dependent on 
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customer service. Therefore, it plays a concrete role in ensuring equal access to 
pharmaceutical care. 
The patient is more likely to purchase the necessary medicinal product if the 
purchasing process is easy and pleasant. The Finnish and Norwegian legislator has 
taken this into account in its regulation regarding pharmacy facilities and opening 
hours. Furthermore, the aim of improved customer service is a central reason why 
pharmacies are run as private businesses in both countries instead of as publicly 
owned healthcare units. 
In connection with generic substitution, Finland expanded the requirement of 
providing information and guidance to cover over-the-counter drugs as well as the 
prices of medicinal products. Also the legislator in Norway took into account the role 
of pharmacies as information and service providers. Guidance on prices not only 
accelerates price competition but also decreases the asymmetry of information 
between the patient and pharmacy. Proper guidance on medicinal products, prices, 
correct use and possible adverse effects works towards improving the patient’s 
confidence in the product and motivation to use the product correctly. This in turn 
works towards rational pharmaceutical care, makes treatment and preventive care 
more effective and thus frees state resources. In practice, customer service contributes 
to the fulfilment of the right to health as well as improves the state’s capability to 
advance equal access to medicine. 
8.1.2. Allocation of Resources 
It is useful to discuss the idea allocation of resources separately from equal access to 
healthcare. This is a central question in health law but it works closer to the surface 
level of the legal system than equal access. The principle of equal access to healthcare 
deals with the manner in which institutions treat individuals. Scarcity of resources 
restricts the scope and defines the substance of equal access in a factual context. 
Resource allocation in turn deals with the manner in which scarce means are 
distributed in practice. The idea of resource allocation can be used to define the 
substance of equal access to healthcare as well as the substance of the right to health. 
Simultaneously, the requirements of equal access and the right to health, working on a 
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deeper level of sedimentation, are defining factors for the practical outcome of 
resource allocation. 
Resource allocation is a difficult question for the legislator. As discussed in relation to 
health law, within medical care regulation is more open and elastic on the decisions of 
resource allocation by doctors than within pharmaceutical care. Within the pharmacy 
sector the most significant question of resource allocation is the reimbursement 
system for drug costs. The legislator in Finland and Norway was faced by the challenge 
of scarce resources and increasing costs. Therefore, in order to ensure the 
sustainability of the pharmacy system and the existing standard for pharmaceutical 
care, the legislator needed to bring down costs. 
Considerations regarding rational pharmaceutical care and reimbursement status have 
been discussed in relation to the principle of need and equal access to healthcare, and 
they can be seen as exercises in the allocation of resources. The same applies for the 
legislator’s decisions on the level of reimbursement. In deciding on recent savings in 
reimbursement costs, the Finnish legislator has taken into account considerations of 
need and equal access. The increases in drug costs have been allocated in a way that 
the impact is smaller for patients with long-term illnesses or expensive treatments. The 
greater part of the cost increase is allocated to citizens with low drug costs. Since this 
group of people is very large, the impact on an individual citizen is reasonable while 
the savings for the state are significant. 
8.1.3. Drug Safety 
The need for drug safety is clear to anyone already on practical and factual grounds as 
the results of poor drug safety could potentially be drastic. However, in understanding 
the role of drug safety in the legislator’s choices, it should be discussed also from the 
perspective of the right to health. Due to its practical implications, drug safety is a 
significant factor for the fulfilment of the right to health. 
In the pharmacy sector, drug safety in fact imposes a special obligation on all actors in 
the field. Pharmacovigilance is the task of pharmacies, pharmacists, doctors, wholesale 
companies, importers, manufacturers, researchers and public officials. Citizens need to 
trust that all relevant actors in the distribution chain have applied the necessary 
diligence in relation to drug safety. Otherwise, their right to health is jeopardized. 
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Pharmacovigilance also provides data on adverse effects. Access to this kind of 
information and its reliability is also central for the patient’s right to self-
determination. Therefore, in addition to the actors in the pharmacy sector, the 
legislator must ensure that these standards are applied in the pharmacy system. The 
legislator decides on amendments and reforms to legislation always in accordance 
with the requirement drug safety. 
The release of certain OTC drugs to sale outside of pharmacies in Norway included an 
evaluation of the principle of equal access to pharmaceutical care was in relation to 
drug safety. This is for example the reason why not all OTC drugs were included in the 
scope of this amendment. In Finland on the other hand the legislator assessed the 
impact of such a measure differently and only permitted sale of nicotine replacement 
drugs as their impact on public health was thoroughly evidenced. These different 
assessments by the Norwegian and Finnish legislator demonstrate that it is not always 
clear, whether a specific measure is harmful to drug safety. In any case, within 
pharmacy law the requirement drug safety has significant weight. In cases where the 
evidence of a detrimental impact of a measure on drug safety is clear, the right to 
health will provide a strong argument against the adoption of such a measure. 
8.2. Patient’s Right to Self-Determination 
The patient’s right to self-determination is a central principle in health law239. Self-
determination has been ensured in Section 1.2 of the Finnish Constitution and in 
Article 102.2 of the Norwegian Constitution. In the context of health law, self-
determination is related to human integrity, the doctrine of informed consent, the 
right to participate in treatment and the right to information concerning one’s health. 
The role which self-determination has in international treaties and the constitution in 
the countries is indicative of its profound weight in the legal system. 
The Finnish legislator has cited the right to self-determination in its assessment of 
constitutional conformity of generic substitution in the government proposal 
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165/2002. The legislator found that the patient’s right to forbid substitution ensured 
self-determination240. 
The pharmacy’s obligation to provide information and guidance on medicinal products 
and their prices in Finland and Norway supports the patient’s right to self-
determination. The legislator in both countries has discussed the asymmetry of 
information concerning pharmaceuticals. In addition to considerations regarding price 
competition, asymmetry of information impairs the patient’s capability241 to 
participate in decisions regarding treatment and exercise the right to self-
determination. By providing information and guidance, the pharmacy can empower 
patients to exercise their right to self-determination. Affordable prices are in practice a 
prerequisite for the patient’s use of a medicinal product. Therefore, price control and 
policies promoting price competition also support the right to self-determination as 
patients can only exercise this right if they in practice have access to the product which 
they have chosen to use. 
9. Conclusions 
The research objective of this work is to understand why the pharmacy systems of the 
two countries have developed differently, and what kind of legal principles factor into 
their development. The following sections discuss the reasons why there are 
differences in the two systems, and the impact of principles and social development on 
legislation concerning the pharmacy sector. However, before dealing with those 
matters, the similarities between the systems should be discussed and the main 
differences should be summarized. 
First of all, as discussed in relation to the different principles of health law, the main 
objectives of pharmacy policy in Finland and Norway are very similar. As Nordic 
welfare states, the two countries have gone through similar historical, economic and 
societal changes in the past. Even the pharmacy sector itself has been based on similar 
privileges and has faced the same disruptions and changes over the centuries. These 
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days, both countries face the same challenges in the form of ageing population and 
increasing healthcare costs. Furthermore, the geographical features of the countries 
pose a particular challenge in terms of equal access to healthcare. 
Most of the main features of the two countries’ pharmacy systems are similar. Both 
countries apply some restrictions to the ownership and management of pharmacies. 
Finland and Norway both have a long history of pharmaceutical reimbursement. 
Recent developments include the introduction of generic substitution and an internal 
reference price system in each country. Professional standards of pharmacovigilance, 
pharmaceutical service, data protection, privacy, etc. are applied and regulated in a 
similar manner. Many of these features have been introduced in Finland and Norway 
in a similar timeframe. 
From the perspective of function, particularly the question of equal access to 
pharmaceutical care has been resolved with use of slightly different institutions. This 
research finds that the most significant differences between the two systems are 
ownership and establishment under the pharmacy license system, the pharmacy fee, 
and sale of over the counter products outside of pharmacies. In practice, these factors 
have led to different structures in the market for medicinal products in the two 
countries. In Norway, as new international actors have entered the market and retail 
stores also engage in the sale of medicinal products, the interest groups as well as 
their aims within the sector have changed. This may lead to further differences in the 
development of Finnish and Norwegian pharmacy systems. The following chapter 
outlines why these different institutions were chosen in Finland and Norway to serve 
similar functions.  
9.1. Interest Groups in the Legislative Process 
In 2000, before the 2001 law reform was introduced, there were 397 pharmacies in 
Norway and 11,425 inhabitants per pharmacy242. In the same year there were in total 
794 pharmacies (591 pharmacies and 203 subsidiary pharmacies) in Finland and in 
2002, when the number of pharmacies was 799, there were approximately 6,500 
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inhabitants per pharmacy243. These figures highlight the difference between in the 
pharmacy networks of the two countries. At the end of the 1990s, the pharmacy sector 
in both countries faced increasing pressure to reduce costs and serve the public more 
efficiently. 
In 1997 calls for the discontinuation of the pharmacy fee were not adopted as the 
policy of the Ministry of Social Affairs and Health. Instead, price control mechanisms 
were adjusted and a new working group was set up in 2000 to assess the need for 
reforms in the price control and reimbursement system. Finland clearly had a much 
more comprehensive pharmacy network than in Norway and thus the challenges of 
the system were less drastic and less immediate than in Norway. 
Therefore, in the years preceding the 2001 law reform, the pressure for changing the 
pharmacy system was higher in Norway than in Finland. The Norwegian Pharmacy 
Association, together with the Norwegian Association of Pharmacists, opposed the 
2001 reform. During the late 1980s and 1990s they argued actively against calls for 
opening the pharmacy system to free establishment. The Pharmacy Association did not 
succeed in maintaining the license framework and pharmacy fee and assistance system 
of the time. However, it should be noted that in light of some of the Strøm Committee 
members’ proposals, the Pharmacy Association did not fully fail either – free 
establishment of pharmacies was not included in the final law proposal. 
In its arguments regarding the ways in which the Norwegian pharmacy sector 
derogated from a perfectly competitive market, the Strøm Committee highlighted the 
positive impacts of competition. The view that competition would force the pharmacy 
sector to cut costs and develop was shared by the Ministry of Social Affairs and Health. 
Furthermore, in the government proposal regarding the 2001 law refom in Norway, 
the Ministry portrayed the pharmacy sector as a conservative profession averse to 
change.244 
In its proposal the Ministry listed the following potential improvements which would 
follow from a more free establishment policy and license system for pharmacies: 
better customer service, lower prices, better access to pharmacies, leveling out of 
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differences in profit between pharmacies, better use of pharmaceutical competence, 
new management competence from outside fo the pharmacy profession, development 
and use of new technology and the use of business entity types which are more 
suitable for the pharmacy’s activities than sole proprietorship.245 
It is clear from the views of the Strøm Committee and the Ministry, that prior to the 
law reform, the Norwegian pharmacy sector had not demonstrated a will to reduce 
costs and improve efficiency. The Pharmacy Association’s argumentation focused on 
drug safety and guidance towards the public. However, pharmacy owners did not 
adopt a strategy in which they would have renewed their business in market terms. 
The approach of arguing against reform resulted in the Ministry’s mistrust toward the 
sector and its capability for renewal. 
In Finland however, the prospect of abolishing the pharmacy fee and the pressure to 
reduce costs motivated the pharmacy sector to renew itself. Pharmacy owners needed 
to improve their business in preparation of possible drastic changes in the license 
framework. Furthermore, they needed to demonstrate the significance of pharmacies 
in ensuring rational pharmaceutical care. Finnish pharmacy professionals participated 
in the process of introducing generic substitution in Finland. The Pharmacy Association 
worked towards improving guidance on OTC drugs through its 1997 strategy for 
professional pharmacies and through a joint project between professional pharmacy 
associations, education facilities and public officials246. Currently, the Ministry of Social 
Affairs and Health, Fimea and professional pharmacy organizations are cooperating in 
order to benefit more efficiently from the pharmaceutical expertise in pharmacies. The 
Ministry has proposed to develop the pharmacy sector in line with the upcoming 
changes in the overall social- and healthcare system, for example by improving services 
and developing new services which pharmacies could offer in the healthcare market247. 
In my opinion, the main reasons why the two pharmacy systems, based on similar 
regulatory frameworks still in the 1990s, have developed differently are as follows. 
Firstly, despite the similarities in the legislative choices for the pharmacy systems, the 
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license regime in Norway and Finland worked differently. By the end of the 20th 
century, the Finnish license system had been more successful in ensuring a 
comprehensive pharmacy network that covered also sparsely populated areas. The 
Norwegian license system on the other hand did not service the public sufficiently. 
Secondly, the Finnish pharmacy sector was ready to improve service on its own terms. 
Norwegian pharmacists however did not demonstrate a similar willingness to improve 
and renew their business. This in turn led to the Ministry’s perception that in opposing 
the law reform, the Norwegian pharmacy sector was aiming at maintaining the 
privileges of pharmacy owners at the expense of public interest. 
9.2. Principles in the Legislative Process 
Much of the legislation concerning the pharmacy sector can be described as 
instrumental in nature and at times even interventionist. Many questions such as the 
reimbursement rate for medicinal products under the national social or health 
insurance scheme are seen primarily as budgetary or political questions. This view 
represents the pragmatic aspect of legislation248. In relation to this kind of regulation, 
discovering the legislator’s aims, the voluntas of law, is a fairly straightforward process. 
However, this work has also discussed the principles which guide the legislator’s 
choices.  
One of the aims of comparison under this work is to understand why the pharmacy 
systems in the two countries are similar or different. An examination of voluntas and 
the arguments directly cited by the legislator provides answers on the vibrations on 
the surface of the legal system. The principles of health law work in the deeper 
structures of the legal system. Their role in the legislator’s policies and choices has 
been discussed in section 8. Within health law, medical ethics and the principles of 
health law are central in ensuring the ratio of law.   
Based on the review of the Finnish and Norwegian legislator’s reasoning for legislative 
measures, the role of principles of health law within the respective pharmacy systems 
is significant. This research shows that many of the relevant fundamental rights and 
social human rights have in fact had an impact on the substance of pharmacy policy in 
each country. In some cases, the legislator has cited fundamental or social rights in its 
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valuation of the best legislative strategy. Furthermore, in my opinion, the policies 
adopted by the legislator have been determined by principles of health law to a 
significant degree even when the legislator has not directly cited them in its 
argumentation. 
Principles such as right to health and the patients’ right to self-determination have 
been embedded in the sediments of legal culture both countries under comparison. 
They impose requirements on the services which the state provides to citizens. 
Principles of health law however also impact the substance of the policies and the 
horizontal rights of citizens in relation to each other. They determine the substantive 
manner in which resources are allocated in the pharmacy sector. Therefore, even in 
situations where legislative measures are introduced in response to scarcity of 
resources, these principles provide guidance on how the impact of public savings 
should be distributed among citizens.249 
Health law includes an ethical dimension250. The value of human dignity, which is 
embedded in deeper levels of the legal system, is recognized as an undeniable 
professional standard in healthcare. Medical ethics is horizontally connected to the 
principles of health law and has an impact on the prima facie priority between 
principles. For example, in valuations regarding prioritization, whether it is in case of 
an individual medical procedure or in decisions of healthcare policy, significant weight 
is given to the right to life and the underlying value of human dignity251.  
9.3. Impact of Social Development on Pharmacy Legislation 
The legal system changes as a response to social development. Changes in society and 
social ideology impact the development of the legal system through its institutions and 
sediments. The surrounding facts impact the substance of the legislator’s choice. The 
practical challenges which the Norwegian legislator had to resolve and the different 
approach which it took in comparison to Finland works as an example. The relevant 
legal principles in the two legal systems were very similar; however the difference in 
factual circumstances warranted different responses. 
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In a welfare state, justice is a central value in society and the state has an obligation to 
uphold and promote it in its policies. Within healthcare, justice is fulfilled by ensuring 
equal treatment and rational care, determined through fundamental rights, human 
rights, ethical standards and healthcare legislation. These standards of justice should 
also be applied to private service providers such as pharmacies. Furthermore, it can be 
argued that on the grounds of their engagement in activities relating to health, private 
actors are bound by these standards even in the absence of direct regulation by the 
state. Nevertheless, it is the task of the legislator to decide on resource allocation and 
to ensure that the healthcare system functions in a just manner in practice.252 
Since the 1980s, the Nordic welfare state model has faced numerous challenges in 
terms of scarce resources. Social human rights are emphasized in welfare state 
thinking. However, recent developments in society and particularly in welfare state 
economy has highlighted neoliberal thinking. In this discussion, social human rights 
which are more collective in nature are pitted against individual human rights and 
freedoms253. This has led to calls for privatization of state functions and use of free 
market mechanisms to achieve greater efficiency. In my opinion, neoliberal ideology 
had an impact in the development of the Norwegian pharmacy system even as full 
liberalisation of pharmacy ownership was not introduced. 
9.4. Final Remarks 
In my opinion, public discussion regarding legislation in the health sector reflects an 
interventionist and instrumental approach to regulation. Positivist thinking plays a role 
in emphasizing the legislator’s sovereign power and political aims. This research shows 
that legal principles play a role in the legislator’s choices and in day-to-day healthcare. 
In times where the legislator is faced with significant pressure to cut costs, the 
substance and role of these principles should be brought to light more effectively in 
the legislative process. 
In discussing the increased role the legislator’s intention, Tuori introduces three 
legislative strategies. Under the instrumental method, decisions are based on the idea 
of applying means to achieve an aim. The substance of instrumental legislation is often 
                                                     
252
 Pahlman, Irma, Potilaan itsemääräämisoikeus p. 100–101. 
253
 Pahlman, Irma, Potilaan itsemääräämisoikeus p. 105, p. 114. 
109 
 
dictated by political or economic considerations. In the strategic method on the other 
hand, the legislator bases the outcome on a compromise of benefits and arrangements 
between interest groups. The third method is based on a consensus achieved through 
discourse. Under this discursive method, the legislative outcome receives its legitimacy 
from the public discussion surrounding the decision-making process. According to 
Tuori, the discursive legislative process is an ideal in which special interests and public 
interest are filtered through the democratic parliamentary process.254 
In my opinion, the ideal of discursive legislation should be adopted as the goal for 
decision-making regarding healthcare regulation. This is particularly important due to 
the nature of health law. By highlighting the importance of legal principles in 
healthcare, public discussion can contribute to ensuring that regulation does not result 
in restrictions to fundamental rights. The nature of health law however poses a 
particular challenge in this respect. Medical expertise plays a significant role in 
determining the substance and weight of these principles in practical situations. For 
example, in order to achieve rational pharmaceutical care, the state must rely on 
pharmaceutical expertise to determine reimbursement criteria for medicinal products. 
The specialization required to make practical decisions regarding health is prone to 
exclude many actors from discussing the substance of health legislation.  
On the other hand, if the views and valuations of healthcare professionals and experts 
are not brought to the legislator’s attention, the risk of legislation based on budgetary 
considerations or compromises between interest groups rather than on principles of 
health law increases. This may even result in regulation which does not serve the 
purposes for which the legislator has intended it. 
Furthermore, ethical decisions regarding health are relevant to everyone in society. 
Ethical decisions should reflect the morality of society and should not be reserved only 
to those with the professional expertise in that specific field. Therefore, there is a need 
for discussion and transparency between medical considerations, ethics and the 
regulatory aspect of the healthcare system. Sen discusses the importance of public 
reasoning and debate in ethics. Within his theory, public reasoning can ensure that the 
requirement of objectivity is fulfilled – if the group of people participating in decision-
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making is small or very similar, there is always a greater risk of misconceptions or 
personal opinions influencing the outcome255. Objectivity in turn improves the quality 
of the decision-making and brings it closer to the requirements of justice. Public 
discussion is also necessary for ensuring that the interest of vulnerable groups which 
are in need of protection but do not have the capability to fully voice their opinion is 
taken into consideration in the legislative process256.  
I find that discourse regarding health law and legislation regarding healthcare has not 
reached its full potential. Healthcare professionals should be more active in voicing 
their concerns and views in the public257. There is a need for bridging the gap between 
considerations based on medical expertise and policymakers. The public should strive 
to educate itself in medicine and the special requirements of the healthcare sector and 
medical ethics. However, the main responsibility for disseminating information and 
engaging the public in questions of health lies on doctors, pharmacists and other 
healthcare professionals. The legal profession should pay close attention to this public 
discussion and participate in it actively. In particular, with their views on the principles 
of health law, lawyers can, and should, contribute to the substantive valuations made 
by healthcare professionals in practical cases as well as to policies and decisions of the 
legislator. 
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